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ABSTRACT

Modulation of gene expression and DNA adduct formation by
chlorophyllin in human mammary cells exposed to benzopyrenes
Kaarthik John
This study investigated metabolic activation by benzopyrenes (BP and B[e]P) in
human mammary cells and modulation by chlorophyllin (CHL, a chemopreventive agent).
Among 6 NHMEC strains monitored using microarrays, 54 genes were up-regulated and 11
down-regulated by signal log ratio (SLR) ≥ 1.5 on treatment with BP alone. Pre CHL +
post BP+CHL treatment up-regulated the expression of 129 genes and down-regulated
those of 35 genes by SLR ≥ 1.5. Studies on CYP1 gene induction and BP-DNA adduct
formation among 20 NHMECs revealed wide inter-individual variations both in the
induction (3-96-fold for CYP1A1 and 4-43-fold for CYP1B1, respectively) and modulation
(2-54-fold and 1-39-fold for CYP1A1 and CYP1B1, respectively) of CYP1 gene expression
and reduction of BP-DNA adduct formation (0% to 86%) on treatment with BP±CHL.
B[e]P was a very poor inducer of CYP1 gene expression and also exhibited no detectable
adduct formation among the 2 NHMEC strains used, when compared to BP. There was a
reduction of BP induced CY1A1 (0-40% among the 2 cell strains) and CYP1B1 expression
(5-50% among the 2 cell strains) across all CHL treatments except for pre CHL+ post BP
treatment and pre CHL + post BP+CHL treatment in one of the cell strains. CHL enhanced
B[e]P induced CYP1 gene expression on treatment of cells with B[e]P + CHL and pre CHL
+ post B[e]P + CHL. When MCF-7 cells were compared to NHMECs, though basal
CYP1B1 expression was nearly 348 times that of CYP1A1, MCF-7 cells exhibited highly
inducible CYP1A1 expression (114 fold) compared to CYP1B1 expression (5 fold). None of
the different CHL treatments modulated CYP1 gene expression or BP-DNA adduct
formation in MCF-7 cells as opposed to NHMECs. When MCF-7 cells were compared to
M00012, a NHMEC, across a range of CHL concentrations, only 3μM, 4μM and 16μM
CHL mitigated CYP1 expression to different extents. BP-DNA adduct levels were
unaltered in MCF-7 cells but reduced in concentration dependent manner in M00012.
These studies show the wide inter-individual variability in response to carcinogens and
chemopreventive agents which are to be accounted for while designing intervention
strategies.
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1.0 INTRODUCTION

Human exposures to various compounds such as polycyclic aromatic hydrocarbons
(PAHs), halogenated hydrocarbons (HHs), aromatic amines (AAs), microbial toxins, drugs
and other xenobiotic compounds occur through diet, occupation, medicines and/or
environment. Benzo(a)pyrene (BP) is a PAH found in tobacco smoke, vehicle exhaust,
indoor heating and various industrial processes, and it is a ubiquitous environmental pollutant
and potent procarcinogen (IARC 1987; Osborne et al. 1987). On entering the body it can
follow a number of routes some of which lead to its bioactivation or detoxication.
Metabolic activation of PAHs (e.g., BP) is necessary for them to exert their adverse
biological and carcinogenic effects, and cytochrome P450 metabolism is a key factor in this
process. Cytochrome P450s (CYPs) constitute a superfamily of heme thiolate proteins, that
are likely the most important classes of enzymes involved in the metabolism of all
xenobiotics (Guengerich 2001). Through their action, together with other enzymes (epoxide
hydrolases) the bioactivation of BP proceeds, leading to the generation of highly reactive
electrophiles capable of damaging cellular macromolecules such as DNA, RNA and protein
(Weston et al. 2005). In addition, CYP450s have a normal role in hormone metabolism, and
since BP acts to generally induce the activity of a range of CYP450s through activation of the
aryl hydrocarbon receptor, BP and other PAHs may be a significant factor in hormonal
carcinogenesis
BP, by acting as a ligand for the AhR, enters the cell and induces CYP genes (OeschBartlomowicz et al. 2005). CYP1A1, CYP1B1 and CYP3A4 are the predominant CYP
isoforms documented to be involved in the metabolism of BP. The predominant pathway of
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metabolism involves the initial oxidation of BP by CYP1A1/CYP1B1 at the 7, 8 position
followed by hydrolysis by epoxide hydrolase to dihydrodiols and then further oxidation at the
9, 10 olefinic bond to yield dihydrodiol epoxides, which being highly electrophilic bind
covalently to DNA leading to genetic damage (Weston et al. 2005). CYP1A1 and CYP1B1
are also potent steroid hydroxylases with CYP1B1 being a potent estradiol 4 hydroxylase. 4OHE2 has been shown to possess a strong cell proliferative effect in various estrogen
responsive tissues such as those of the breast and the endometrium and is thereby implicated
in their carcinogenesis (Cavalieri et al. 2002).
Given the ubiquitous nature of BP, a complete avoidance of exposure may be
difficult. Chemopreventive agents that block or even reverse the carcinogenic process may
therefore be a useful alternative consideration. CHL, a water soluble sodium-copper or
potassium-copper metalloporphyrin has been shown to exhibit anti-carcinogenic, antimutagenic, anti-tumorigenic and anti-oxidant properties in various studies and model systems
(Sarkar et al. 1994; Tachino et al. 1994; Dashwood 1997a; Reddy et al. 1999; Kamat et al.
2000). It has also been used as a safe and effective intervention strategy in various
developing parts of Africa and China with populations at high risk for developing
hepatocarcinoma (HCC) due to the regular consumption of aflatoxin contaminated foods
(Kensler et al. 2004).
Due to its carcinogenic properties, BP has been a compound of intense research
interest since its isolation in the 1930s. However, very few studies have been conducted on
the effect of BP on genome wide gene expression patterns, effect of intervention agents on
modulating these expression patterns on a genomic scale and in turn the effects of this
modulation to the individual in question. In addition, malignantly transformed cells are often
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used as alternatives to normal cells in in vitro studies due to their ease in maintenance and the
assumption of their similarity to normal cells in response to carcinogenic stress. However,
whether or not malignantly transformed cells are appropriate models to use in studies of
metabolic activation and chemical carcinogenesis is an important question to consider.
This dissertation considers the metabolism and activation of an important,
carcinogenic polycyclic aromatic hydrocarbon to which everyone is exposed. It further
considers inter-individual variation in certain metabolic factors that impact an individual’s
risk of cancer, and it examines the extent to which these factors may be mitigated by the
introduction of a chemical intervention.
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Objectives
The goals and objectives of these studies were to:

•

Assess genome-wide changes in gene expression patterns among a panel of 6 normal
human mammary epithelial cells (NHMECs) on exposure to BP in the absence or
presence of CHL in order to seek biomarkers for chemopreventive intervention.

•

Determine the extent of inter-individual variation in CYP1A1 and CYP1B1 gene
expression among a larger panel of 20 NHMECs on exposure to BP in the absence or
presence of CHL.

•

Determine the extent of inter-individual variation in BP-DNA adduct formation
among a larger panel of 20 NHMECs on exposure to BP in the absence or presence of
CHL.

•

Examine BP and B[e]P in parallel for their effect on CYP1A1 and CYP1B1 gene
expression and DNA adduct formation in 2 NHMECs in the absence or presence of
CHL.

•

Examine NHMEC(s) in parallel with a cancerous cell line, MCF-7 for their effect on
CYP1A1 and CYP1B1 gene expression and DNA adduct formation on exposure to BP
in the absence or presence of CHL.
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2.0 REVIEW OF LITERATURE

2.1 Introduction

Cancer is the second largest cause of mortality next only to cardiovascular diseases.
Nearly 1.4 million new cancer cases (excluding noninvasive cancer) are expected to be
diagnosed in the US in 2006 and more than 500,000 will die (http://www.cancer.org). A large
proportion of these cancer deaths are attributable to nutrition, lifestyles and occupational
exposures to many carcinogens.
Cancers arise in epithelial tissues (carcinomas), mesenchymal tissues (sarcomas),
haemato-lymphoid system (leukemias and lymphomas) and other tissues of the body
(Knowles et al. 2005). These cancers are both benign and malignant.
Human exposures to a range of chemicals and toxins many of which may be
potentially carcinogenic occur through air, water, diet, lifestyle and/or occupation.
Biotransformation and metabolism of many of these chemicals are the primary cause of toxic
manifestations. Cytochrome P450s (CYPs) form the major superfamily of enzymes involved
in many of these Phase I metabolic reactions in addition to their roles in steroid genesis and
drug metabolism. Given the widespread distribution and potentially multiple routes of
exposure of many of these chemicals alternative strategies involving the use of
chemopreventive measures to block or even reverse some of the genetic damage induced by
these agents may be a viable approach.
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2.2 Chemical carcinogenesis

Chemical carcinogenesis typically involves a complex series of events starting with
the bioactivation of the chemicals to DNA damaging metabolites followed by damage of
cellular macromolecules and mutation fixation. Reports on increased incidences of nasal
polyps among dippers and enhanced rates of scrotal cancer in English chimney sweeps were
some of the early documented cases of chemical carcinogenesis (Poirier 2004).
Early chemical carcinogenesis studies in the 1930s with attempts to isolate some of
the carcinogenic constituents of coal tar has progressed rapidly ever since (Phillips 1983). An
important landmark was the understanding that binding of reactive electrophiles (in case of
genotoxic agents) to cellular macromolecules being associated with enhanced risk of
carcinogenesis. However, these early studies believed the interaction to occur with proteins
rather than DNA (Miller 1951). The work by Brookes and Lawley served to be some of the
seminal work which demonstrated the binding of PAHs to DNA and its correlation to
carcinogenicity (Brookes et al. 1964). Subsequently, it has also become known that free
radicals that may be generated by CYP mediated catalytic cycling of xenobiotics could also
potentially cause free radical damage of cellular macromolecules. Non-genotoxic agents may
cause damage by oxyradical formation, depurination, toxic cell death or even by modifying
the effects of genotoxic agents (Yuspa et al. 1997). All these can be involved in the
multistage process of chemical carcinogenesis that can be conceptually divided into 4
component process: tumor initiation, tumor promotion, malignant conversion and tumor
progression.
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Tumor initiation is a rare event the frequency of which is dependent on the carcinogen
dosage. It may involve DNA adduct formation (as in case of genotoxic agents) leading to the
inactivation of tumor suppressor genes and/or activation of protooncogenes or events such as
methylation of the promoters of tumor suppressor genes (as in case of non-genotoxic agents)
leading to their silencing. This requires the changes to occur in a population of dividing cells
so as to ‘fix’ the mutations. In general a strong correlation has been observed between the
extent of DNA adduct formation and tumor formation.

Tumor promotion involves a clonal expansion of the initiated cells. Tumor promoters are
agents that are generally non-mutagenic and non-carcinogenic by themselves but which
enhance the carcinogenicity of tumor initiators. These usually possess multiple mechanisms
of action and generally do not require any metabolic activation for the activity. They mainly
serve to reduce the latency period for tumor formation when dosed in conjunction with the
initiator. Tumor promoters generally bring about their effects through activation of cell
surface receptors, stimulation of cell proliferation, perturbation of signal transduction
pathways, inhibition of apoptosis or by modulation of cytosolic and nuclear factors. Agents
capable of functioning both as a tumor initiator and promoter are regarded as complete
carcinogens e.g.: 4-amino biphenyl. Tumor promotion is considered the chief rate limiting
step in experimental carcinogenesis.

Malignant conversion involves accumulation of further genetic changes leading to the
transformation of preneoplastic cells to express a malignant phenotype. This often involves
multi-focal changes in premalignant lesions such as up-regulation of AP-1, gene
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amplification, exposure of cells to DNA damaging agents and over-expression of cell cycle
regulatory proteases. The changes occurring may be reversible where regression of lesions
occur when the promoting agent is removed prior to malignant conversion.

Tumor progression involves acquisition of more aggressive characteristics by the malignant
cells facilitating their spread and invasion beyond the primary site and often involves events
such as complex genetic alterations (translocations, deletions, gene amplifications,
duplications), ectopic changes in hormone production and activation of protooncogenes
(through point mutations or gene amplifications) and inactivation of tumor suppressor genes.

2.3 Chemical classes
2.3.1 Polycyclic aromatic hydrocarbons (PAHs)
PAHs are a class of more than 100 known compounds that are composed of variable
numbers of fused benzene rings. They are ubiquitous environmental pollutants formed from
the incomplete combustion of organic matter and are also generated as by-products from
various industrial processes. Pure PAHs are usually colorless, white or pale yellow solids,
generally odorless, but in some cases have a mild faint odor. These compounds almost most
occur as complex chemical mixtures in nature.
Considerable interest in PAHs stems from the ability of many of them to cause
toxicity and cancers of various organs (Ramesh et al. 2004). PAHs are chemically inert, and
they require metabolic activation to exert their biological effects (Weston et al. 2005).
Benzopyrenes, are members of the PAH family of compounds. Two of these benzo(a)pyrene
(BP) and benzo(e)pyrene (B[e]P) were used in various experiments in this study.
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Benzopyrenes
Benzopyrenes, prototypical carcinogens found generally with various other PAHs in
tobacco smoke, charbroiled foods and in the combustion products of organic matter and
various organic fuels are ubiquitous environmental pollutants (Hooven et al. 2005). BP, a
highly carcinogenic PAH, has been a compound of extensive research interest since its first
isolation by Kennaway et. al., in 1930s from 2 tons of coal tar pitch (Kennaway 1955).
According to the International Agency for Research on Cancer (IARC) it has been placed
under Group 2A (probably carcinogenic to humans) (IARC 1987). The structure of BP is
shown in Figure 1(A).

Figure 1: (A) Benzo[a]pyrene (BP)

(B) Benzo[e]pyrene (B[e]P)

B[e]P is a structural isomer of BP. The low carcinogenicity of B[e]P in contrast to
BP has caused very few studies to be carried out on B[e]P compared to BP. B[e]P is only
weakly mutagenic and carcinogenic compared to BP and has been assigned IARC rank of
Group 3 (not classifiable as to the carcinogenicity to humans) (IARC 1987). The structure of
B[e]P is presented in Figure 1(B).
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However, because it is found with BP and other highly carcinogenic hydrocarbons in
the environment, its effect on modulating the carcinogenicity of these hydrocarbons is to be
addressed.

2.3.2 Aromatic amines and heterocyclic amines
Aromatic amines are carcinogens present in tobacco smoke, diesel exhaust and some
cooked foods. They consist of one or more rings of unsaturated or cyclic hydrocarbons along
with nitrate (NH2) groups. They are implicated in cancers of the bladder, colon and ureter
(Weston et al. 2005).
Heterocyclic amines are formed from high temperature cooking of foods (>1500C)
mainly from pyrolysis of the amino acids, creatine and creatnine and sugars such as glucose.
These substances have been found to be potent mutagens in Ames Salmonella assay and are
carcinogens in laboratory animals (Layton et al. 1995). These have also been found to form
liver tumors in primates (Adamson 1989).

2.3.3 Aflatoxins
These are chemicals which represent a family of structurally related
difuranocoumarin derivatives produced by certain fungi (Aspergillus flavus and A.
parasiticus) that contaminate peanuts, soybean and certain cereals. The production of theses
toxins are affected by environmental and strain specific factors (Sudakin 2003). Aflatoxin B1
and G1 are more mutagenic and carcinogenic than aflatoxin B2 and G2 (Weston et al. 2005).
Exposure to aflatoxin B1 has been shown to be linked to enhanced risk of liver cancer in
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human populations exposed to dietary aflatoxins in certain parts of China and Africa
(Kensler et al. 2004).

2.3.4 N-nitrosamines
These are ubiquitous environmental pollutants found in certain foods such as cured
meats, alcoholic beverages, certain cosmetics, oils and tobacco. N-nitrosamines can also be
formed endogenously through nitrosation where an amine reacts with nitrate alone or in the
presence of acid (Weston et al. 2005). Exposures to dietary nitrosamines have been
associated with risk of esophageal and gastrointestinal cancers while exposure to tobacco
specific nitrosamines such as 4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanone have been
associated with enhanced risk of lung cancer (Goldman et al. 2003).

2.3.5 Non-genotoxic agents
These are mainly agents which tend to bioaccumulate in biological systems (e.g.:
pesticides, herbicides) and cause disease upon prolonged exposure. There is no conclusive
evidence of their role in causing cancers but they may modify the effects of some of
genotoxic carcinogens. In other cases they may manifest their effects by causing toxic cell
death, oxyradical formation, disruption of hormonal balance, dysregulation of growth factors
and by disruption of certain signaling pathways (Yuspa et al. 1997; Weston et al. 2005).
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2.4 Metabolism of carcinogens
Once internalized most chemical carcinogens are subject to competing processes of
metabolic activation (Phase I reactions) versus detoxication (Phase II reactions). The
metabolic route of some of the chemical classes listed above is discussed below.

2.4.1 PAHs
Benzopyrenes
BP is one of the best characterized PAHs whose metabolism has been studied
extensively. It acts as a ligand for Ahr, a basic helix-loop-helix (bHLH)/Per-ARNT-Sim
(PAS) homology domain family of transcription factors. Various other planar aromatic
compounds and many of their halogenated derivatives also act as Ahr ligands. BP has been
found to be a strong Ahr ligand while B[e]P a weak Ahr ligand (Sterling et al. 1994). In
vertebrates, Ahr exists in the cytosol complexed with a dimer of Hsp90 and several Hsp90
accessory proteins (Puga et al. 2005). Ahr ligands following entry of the cell by diffusion,
bind Hsp90 associated Ahr and subsequently cause a conformational change in Ahr leading
to its increased affinity for DNA. The conformation change causes liganded Ahr to
translocate to the nucleus, exchange Hsp90 for Arnt (aryl hydrocarbon nuclear translocator),
another bHLH/PAS transcription factor ultimately leading to the formation of an Ahr, Arnt
and ligand complex. This complex in turn binds to xenobiotic response elements (XRE) in
the upstream regions of CYP genes leading to their enhanced transcription (Schmidt et al.
1996; Vrzal et al. 2004). In some rare cases unliganded Ahr has been found to undergo
nuclear translocation and it is suggested that a universal secondary mediator like cAMP may
play a role in this mechanism (Oesch-Bartlomowicz et al. 2005).
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Many studies on the mechanism of BP metabolism occurred during the period
between 1950 -1990. The metabolism of BP generally proceeds in 2 phases; Phase I involves
the conversion of BP to oxidized derivatives (epoxides, phenols, diols and quinines) and
Phase II reactions involve the conversion of these derivatives to polar metabolites by
conjugation with sulfate, glucuronic acid or glutathione (Osborne et al. 1987).
The primary metabolites are three epoxides: 4,5-epoxide, 7,8-epoxide, and 9,10epoxide while 1,2-epoxide and 2,3-epoxide are theoretical intermediates that are nonenzymatically converted to phenols. 4, 5-epoxide is the most stable of the epoxides that can
be isolated. These products of initial oxidation are generated by the action of various CYPs
principally CYP1A1, CYP1B1 and CYP3A4. The epoxides can subsequently be hydrolyzed
to the corresponding trans-diols/dihydrodiols (t-4,5 diol, t-7,8 diol or t-9,10 diol) by the
action of epoxide hydratase (EH) or be converted non-enzymatically to phenols or undergo
conjugation by glutathione S-transferases to form the corresponding glutathione conjugates
(Gelboin 1980). Diols formed can exist in either the cis or trans configuration. All diols
formed from PAHs other than BP in the presence of mammalian microsomal enzymes exist
in the trans configuration. However, all diols formed enzymatically from BP are trans and (-)
enantiomers of high optical purity (Gelboin 1980).
1-OH, 3-OH, 6-OH, 7-OH and 9-OH are the 5 major phenol metabolites (with the 3OH, 7-OH and 9-OH metabolites being the most common) which can subsequently be
converted to quinones/diones (1,3 quinone, 3,6 quinone and 6,12 quinone) or be conjugated
to glucuronic acid by UDP glucuronsyl transferases (encoded by 2 gene families, UGT1 and
UGT2 with several sub-families and members) to yield glucuronide conjugates. The
glucuronide conjugates may be acted upon by β-glucuronidase present in the intestinal
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microflora to release the parent compound, which, being electrophilic may attack DNA and
other cellular macromolecules (Parkinson 2003). The quinones formed from the phenols may
be conjugated to sulfates by sulfotransferases (encoded by 5 gene families, SULT1-SULT5
with several subfamilies) and subsequently be converted to the corresponding sulfate
metabolites or be conjugated to glutathione to produce glutathione conjugates (Guillen et al.
2003). The phenols may also be directly converted to sulfate metabolites by the action of
sulfotransferases. The formation of phenols, sulfates, glutathione and glucuronide conjugates
are all considered to be more of detoxification pathways enhancing the hydrophilicity of the
compounds and therefore aiding in their excretion from the system. Dihydrodiol metabolites
can undergo further oxidation by CYPs (mainly CYP1B1 and CYP3A4) to produce
dihydrodiol epoxides (Gelboin 1980) or may undergo conversion to more polar phenol diols
(6-OH-7,8 diol, 1-OH-9,10 diol, 3-OH-9,10 diol, 9-OH-4,5 diol).
The two common stereoisomeric dihydrodiol epoxides (of 4 possible forms) are r-7,t8 diol c-9,10 hydroxy BP/ (±)7α,8β-dihydroxy-9α,10α-epoxy-7,8,9,10 tetrahydroBP
(BPDE1/syn isomer /cis isomer) and r-7,t-8 diol t-9,10 dihydroxy BP/ (±)7α,8β-dihydroxy9β,10β-epoxy-7,8,9,10 tetrahydroBP (BPDE2/anti isomer/trans isomer) (Kim et al. 1998;
Rubin 2001). The preferred oxygenation site and subsequently the preferred dihydrodiol
epoxide formed appears to depend on the CYP isoform catalyzing the process and hence is a
function of the tissue or enzyme preparation used (Gelboin 1980). Both BPDE1 and BPDE2
are reactive capable of binding to DNA, RNA and proteins forming bulky covalent addition
compounds called adducts. The first experimental evidence that the anti isomer of BPDE
may be the ultimate DNA binding metabolite was from work of Sims et. al. (Sims et al.
1974). Both, BPDE1 and BPDE2 form a C-10 carbonium ion intermediate which is
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responsible for their reactivity towards cellular nucleophiles such as DNA and proteins.
Among the two stereoisomers BPDE2 has been found to be even more reactive than BPDE1
and hence has been studied extensively (Kim et al. 1998). Both diol epoxides however are
unstable in aqueous media and are hydrolyzed spontaneously to tetrols. BPDE1 can be
hydrolyzed to 2 tetrols, (±)BP r-7,t-8 c-9,c-10 tetrahydrotetrol (RTCC), the major tetrol and
(±)BP r-7,t-8 c-9,t-10 tetrahydrotetrol (RTCT), the minor tetrol while BPDE2 can also be
hydrolyzed to 2 tetrols, (±)BP r-7,t-8 t-9,c-10 tetrahydrotetrol (RTTC), the major tetrol and
(±)BP r-7,t-8 t-9,t-10 tetrahydrotetrol (RTTT), the minor tetrol. [The R, T, C system of
nomenclature was suggested by the American Chemical Society where r = relative, the
position to which all other positions relate, t = trans and c = cis]. Both BPDE1 and BPDE2
can be reduced in the presence of NADH or NADPH to the corresponding triols. This
reduction occurs non-enzymatically and is dependent on the tissue concentration of NADH
or NADPH. The triols and tetrols are polar and undergo elimination through excretion. A
summary of these various routes during the metabolism of BP is presented in Figure 2. A
more detailed representation of the pathway leading to metabolic activation and the
formation of adducts is presented in Figure 3.
Metabolically activated BP (BPDE) binds DNA, RNA and proteins. The binding to
proteins may be 10 times greater than to nucleic acids. Apart from BPDE, the oxides as well
as diols are also known bind to proteins and nucleic acids (Osborne et al. 1987). Electron rich
amino acids such as tyrosine, histidine and tryptophan may play a vital role in protein
binding. When binding to DNA, deoxyguanosine appears to be the preferred base though
adducts with all other bases of DNA are also known (Dipple et al. 1984). Some studies have
also found modification of the phosphate backbone of nucleic acids. In case of binding to
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RNA there seems to be some interaction of the diol epoxides with uracil residues (Gelboin
1980). In case of guanine the major site of modification is the exocyclic amino group at
position 2 though a minor product may also be formed at N-7. Adducts are also possible with
the exocyclic amino group at position 6 of deoxyadenosine and the amino group of
deoxycytidine (Dipple et al. 1984). The diol epoxide seems to be the predominant adduct
involved in DNA binding.
Given the lower carcinogenicity of B[e]P compared to BP relatively fewer studies
have been carried out on this compound. Metabolism of B[e]P has been found to yield B[e]P4,5-dihydrodiol, 1-hydroxy-BeP and 3-hydroxy-BeP along with small amounts of B[e]P9,10-dihydrodiol and a few other secondary metabolites. Of these the 4,5 dihydrodiol appears
to be the major metabolite. Other studies have also found an unidentified phenol (probably 1hydroxy-BeP), 3-hydroxy-BeP and a quinone as metabolites but their proportions are much
lower than B[e]P-4, 5-dihydrodiol. However, B[e]P-9,10-dihydrodiol is the only derivative
whose metabolism has been studied. On incubation of this derivative with liver microsomal
about 13% was converted to 9,10-epoxy-11,12-dihydroxy-9,10,11,12-teterahydro-BeP while
the rest was recovered as B[e]P-4,5,9,10-tetrahydrotetrol and 2 triols. 9,10-epoxy-11,12dihydroxy-9,10,11,12-teterahydro-B[e]P reacts directly with DNA, the principal adducts
having C9 of guanine attached to exocyclic N2 of guanine. A few other minor adducts
including ones with deoxyadenosine have also been found (Osborne et al. 1987).
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Figure2: Metabolic pathways of BP. The different routes of metabolism listed here are
however not exhaustive.

Figure 3: The metabolic activation of BP has been widely studied. (1) CYP1A1 and
CYP1B1 catalyze the conversion of the parent compound to arene oxides. (2) Arene oxides
are converted to dihydrodiols by EH (3) The resulting dihydrodiols are further oxidized at the
site of the olefinic bond (4) Vicinal diol epoxides are highly unstable and undergo
spontaneous arene ring opening to yield carbocation. (5) The electrophilic carbocation can
form a covalent bond with exocyclic amino group of deoxyguanosine. The resulting adducts
resides in the minor groove of DNA.
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2.4.2 Aromatic amines and heterocyclic amines
The metabolism of aromatic amines is rather complex. They may be converted to an
aromatic amide catalyzed by acetyl co-enzyme A dependent acetylation or may undergo Noxidation to give N-hydroxylated products which may subsequently be protonated by acidic
conditions in the urinary bladder giving rise electrophiles capable of binding DNA. The
initial activation step of both aromatic amines and amides is through CYP1A2 mediated Noxidation (Weston et al. 2005).
Heterocyclic amines are bioactivated by CYP1A2 mediated N-hydroxylation
followed by enzymatic O-esterification. The nitrenium ion is likely to be the ultimate
carcinogen capable of adduct formation (Goldman et al. 2003).

2.4.3 Aflatoxins
Aflatoxins may be activated by various CYPs (CYP2A3, CYP1A2, CYP2A6,
CYP3A4, and CYP3A5). In case of aflatoxin B1, the process involves a CYP3A4 or
CYP1A2 mediated oxidation at the exo 8, 9 position to form an electrophilic exo 8, 9 epoxide
which can subsequently bind to DNA and proteins and form adducts. Formation of these
adducts has been shown to cause G:C to T:A transversion at codon 249 of the p53 tumor
suppressor gene (Kensler et al. 2004). Formation of CYP1A2 mediated aflatoxin M1 is
considered a detoxification pathway (Sudakin 2003).

2.4.4 N-Nitrosamines
Endogenous nitrosamines form during the reaction of an amine with a nitrate alone or
a nitrite in the presence of an acid. Dietary and tobacco specific nitrosamines constitute some
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of the exogenous sources of nitrosamines. N-nitrosodimethylamine formed from exposure to
nitrosamines undergo enzymatic α-hydroxylation (CYP2E1/ CYP2A6 mediated) to form an
unstable α-hydroxynitrosamine which subsequently hydrolyzes to an aldehyde and a
monoalkylnitrosamine. The monoalkylnitrosamine can subsequently release a carbocation
which can alkylate DNA bases.

2.5 DNA damage
Exposures to carcinogens through various routes lead to DNA damage. The damage
may involve formation of addition compounds by covalent attachment to DNA bases (adduct
formation), alterations in DNA structure (single and double strand breaks, DNA strand crosslinks, chromatid exchanges), oxyradical damage of bases, transitions, transverisons,
dimerization, deamination as well as epigenetic changes (Yuspa et al. 1997; Weston et al.
2005).
Most carcinogens are mutagens causing heritable changes in the structure of DNA.
Different nucleophilic sites on DNA form targets for attack by different adduct forming
species. These include N1, N3 and N7 of adenine, N3 of cytosine, O2, N3 and O4 of
thiamine and N2, O6 and N7 of guanine. DNA adduct formation may involve the addition of
just a portion of the chemical carcinogen such as a small alkyl group (as in the case of
carcinogens like N-nitrosamines, N-alkylureas, mustards and haloalkanes) or the entire
carcinogen leading to the formation of large, bulky DNA adducts (as in case of many PAHs)
(Weston et al. 2005). In many cases these changes lead to the formation of ‘signature’
mutations in certain key oncogenes and /or tumor suppressor genes. For example, in many
cases of tobacco smoke induced lung cancer the common targets for adduct formation appear
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to be the ras oncogene as well as the p53 tumor suppressor gene. Most cases of aflatoxin
induced hepatocarcinomas (from either China or South Africa) were found to harbor G → T
transverisons in the 3rd position of codon 249 of p53 (Yuspa et al. 1997; Weston et al. 2005).
Activated benzopyrenes bind preferentially to the exocyclic amino group of
deoxyguanosine (N2) to form (7R)-N2-(10[7b, 8a, 9a-trihydroxy-7,8,9,10-tetrahydrobenzo[a]pyrene]yl)-deoxyguanosine (BPdG) adducts which appears to be the most common
adduct of BP though adducts with other bases in DNA have also been reported. With regard
to aromatic amines the C8 of deoxyguanosine appears to be the predominant site for adduct
formation though adducts with C8, N2 and O6 are also possible (Weston et al. 2005).
Heterocyclic aromatic amines also have a preference for the C8 and amino groups of purines,
especially deoxyguanosine for forming adducts (Dipple 1995). Aflatoxin B1 and G1undergo
oxidation at the 8, 9-position to form N7 deoxyguanosine adducts. This in turn could undergo
ring opening to form two pyrimidine adducts N-nitrosamines upon metabolic activation
bring about alkylation of DNA at some of the similar sites on DNA bases as mentioned
above though the N7 of guanine appears to be the preferred site.
Apart from these, oxidative damage of DNA from various endogenous and/or
exogenously sources of oxygen radicals can lead to the formation of thymine glycol or 8hydroxydeoxyguanine adducts. The catalytic cycling of BP, endogenous lipid peroxidation
and catalytic cyclic of some enzymes include some of these (Guengerich 2001). Etheno
adducts can result from reaction of the bases in DNA with xenobiotics such as urethane and
chemicals such as carbon tetrachloride and ethanol.
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2.5.1 DNA repair
Maintenance of the genome integrity may be achieved at various levels such as by
prevention of carcinogen activation, prevention of interaction of the activated carcinogen
with the target site, abrogation of the damage caused, or various combinations of these.
Impaired capacity for DNA repair is associated with various cancers and syndromes. More
than 140 gene products are implicated to play roles either directly or indirectly in different
mechanisms of DNA repair mechanisms (Knowles et al. 2005). There are six main
mechanisms of DNA repair: direct DNA repair, nucleotide excision repair (NER), base
excision repair (BER), mismatch repair, non-homologous end joining and homologous
recombination (Yuspa et al. 1997; Weston et al. 2005).
Generically DNA repair involves damage recognition, excision of the damaged
strand, resynthesis and ligation. All these repair mechanisms involve multiprotein complexes
with many of their components being involved in common in more than one repair process
(Weston et al. 2002).
Direct DNA repair involves alkytransferases which remove alkyl moieties from
alkylated bases followed by transfer of the moiety to a cysteine in the active site of the repair
enzyme. The best known example of this mechanism is the removal of O6-methyl guanine.
NER and BER are similar with both involving multi-protein complexes which
recognize the damage, remove the damage, fill in the gaps created and finally seal the nick.
NER however, is employed in the repair of large bulky adducts such as those of
benzopyrenes while BER is typically involved in the removal of smaller alkyl groups.
DNA mismatches involving single base mismatches due to errors in DNA repair or
replication can be corrected by mismatch DNA repair mechanism which involves removal of
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large pieces of mismatched DNA using protein complexes that bind to the mismatch and the
nearest unmethylated adenine in the sequence GATC, followed by resynthesis of excised part
by DNA polymerase and finally ligation by a ligase complexed to the polymerase.
Large bulky adducts such as those of BP can also distort DNA causing it to break. In
addition, other mechanisms such as exposures to ionizing radiations and a damage tolerance
mechanism known as post explicative repair also causes DNA double strand breaks. These
double strand breaks may be repaired by homologous or non-homologous recombination
mechanisms. Homologous recombination involves the simultaneous resection of both strands
followed by invasion of the homologous duplex by 5’ tails of the disrupted DNA, resynthesis
followed by polymerization and ligation.
Non-homologous end joining is a repair mechanism that is homology independent.
The breaks may be symmetric or asymmetric; in case it is asymmetric resection occurs to
create blunt ends before they are joined. This method of repair is therefore prone to
introduction of small deletions in the sequence of the repaired DNA.

2.6 Potential impact on hormonal carcinogenesis
BP is an inducer of steroid hydroxylases, CYP1A1 and CYP1B1, which in turn bring
about the metabolism of BP to reactive intermediates. These enzymes along with CYP3A4
also play a vital role in the oxidative metabolism of two of major natural estrogens, estrone
(E1) and estradiol (E2) (produced by the ovaries) as well as other synthetic estrogens such as
17α ethyinylestradiol (Liehr et al. 1990). The major pathway of estrogen oxidation involves
their P450 mediated hydroxylation to form catechol estrogens (CEs), their 2-OH and 4-OH
derivatives, and 16α-OH metabolite (Cavalieri et al. 1997). Although these CEs can be
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inactivated through conjugation, their incomplete or ineffective conjugation may lead to the
production of reactive semiquinones and/or quinones radicals. These quinones can
subsequently be inactivated by conjugative mechanisms. However, incomplete removal may
allow them to bind to DNA and form stable DNA or depurinating DNA adducts. The
formation of N7 guanine adducts by CE-3,4-quinone is thought to be a tumor-initiating event
(Cavalieri et al. 1997). Apart from this, free radicals generated from the quinonesemiquinone redox cycling of estrogens can lead to free radical damage (Kirkman 1959;
Liehr et al. 1990). Further, the 4-OH and 16α-OH metabolites of estrogen are found to have a
potent cell proliferative effect in estrogen responsive tissues

2.7 Chemoprevention
Given the ubiquitous nature of benzopyrenes a complete avoidance of their contact is
impossible. An alternative more practical approach may therefore involve reducing their
uptake, preventing their metabolism or preventing the activated metabolites from
reaching/interacting with the target site. The use of agents (natural, synthetic, biological or
chemical) which may reverse, suppress or prevent the carcinogenic process at various phases
of the multistep carcinogenic process may form a viable strategy. This constitutes the concept
of chemoprevention. Though known for about four decades or so a greater insight into the
idea was brought by two pioneers in the field, Lee W.Wattenberg and Michael B. Sporn.
Initially called ‘chemoprophylaxis of carcinogenesis’ by Wattenberg (Wattenberg 1966), the
term ‘chemoprevention’ was coined only later by Sporn et al., (1976). The original concept
of chemoprevention was to inhibit or delay the occurrence of cancers by agents that would
block one or more pathways in the induction of cancer. However, the concept has expanded
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over the years to include agents which would even reverse the carcinogenic process by
transforming malignancy to pre-malignancy.

2.7.1 Chemopreventive agents
Currently there are approximately 400 compounds being studied as potential
chemopreventive agents of which around 10% are in clinical trials
(http://www.cancer.gov/cancertopics/factsheet/Prevention/chemoprevention).
Chemopreventive agents can be classified into 4 main categories: blocking agents, agents
reducing tissue vulnerability to carcinogenesis and suppressing agents (Wattenberg 1997).
Blocking agents act through prevention of carcinogen activation, enhancement of
carcinogenic detoxification or prevention of activated metabolites from reaching critical
target sites. Agents reducing tissue vulnerability to carcinogenesis act through effecting
cellular maturation, reducing the activity of the target cells, decreasing cell proliferation or
modulating signal transduction and hormone/growth factor activity.
Suppressing agents prevent the evolution of the neoplastic process in cells that may be on the
verge of becoming malignant. Some suppressing agents may act by producing differentiation
and inhibiting cellular proliferation. Another large group of compounds not fitting into any of
these categories have the capacity to inhibit components of the arachidonic acid pathway and
induce antioxidant enzymes.
Ideal chemopreventive agents are ones which combine multiple mechanisms of
action, have low toxicity, high efficacy, are easily acceptable in intervention strategies and
are economically viable (Egner et al. 2001).
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Chlorophyllin (CHL)
Porphyrins are compounds with four pyrrole nuclei (a five-membered heterocyclic
aromatic ring compound with the formula C4H5N) joined by -CH- bridges.
Porphyrins, both natural as well as modified versions are generally, effective antimutagens and
anticarcinogens against heterocyclic amines and various other mutagens possessing polycyclic
structures. Hemin (the natural porphyrin found in hemoglobin and myoglobin), copper
pthalocyacnin (a blue pigment similar in structure to hemin) and chlorophyll (the green pigment in
photosynthesizing plants) have all been found to be effective antimutagens (Hayatsu 1995). The
structures of these compounds are presented in Figure 4.
Chlorophylls and even more so CHL have been gaining prominence over the last decade as
effective chemopreventive agents (Dashwood 1997b). Commercially available CHL consists
mainly of a trisodium copper salt apart from small amounts of mono- and di-carboxylic acid
chlorins (Dashwood 1997b).
Though several medical and clinical uses of CHL exist (Kephart 1955) its increasing use in
cancer biology stems from its ability to exhibit various activities in in vitro and in vivo studies
making it an attractive chemopreventive agent. Its has been found to be antimutagenic being
effective against various chemicals such as aflatoxin B1, BP, heterocyclic amines, coal dust and
airborne particles (Terwel et al. 1985; Ong et al. 1986; Dashwood et al. 1991; Warner et al. 1991).
Anticlastogenic activities of CHL have been demonstrated in a few studies (Sarkar et al. 1996;
Negraes et al. 2004). CHL has also been shown to exhibit antigenotoxic (Bez et al. 2001; TorresBezauri et al. 2002), anticarcinogenic (Park et al. 1996; Reddy et al. 1999), antioxidant (Kamat et
al. 2000; Kumar et al. 2004)) apoptosis inducing (Diaz et al. 2003; Chiu et al. 2005) and immuno
modulatory properties (Yun et al. 2005; Sharma et al. 2006).
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Hemin

Chlorophyll

Cu –pthalocyanine

Chlorophyllin (CHL)

Figure 4: Structures of some of the biologically important metalloporphyrins. The groups
that differ in CHL compared to chlorophyll are circled. The positions occupied by sodium
(Na) can also be occupied by potassium (K) depending on reaction conditions during the
conversion of chlorophyll to CHL. Commercial CHL is mainly the trisodium salt shown here
along with small amounts of mono-sodium and di-sodium salts.
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The most conclusive evidence of CHL as an anticarcinogenic agent probably comes
from its role in the chemoprevention of hepatocarcinoma (liver cancer) in aflatoxin endemic
areas of the world such as China (Kensler et al. 2004). Chronic hepatitis B virus (HBV)
infection along with exposure to aflatoxins through diet contributes to extremely high risk of
liver cancer in Quidong. Exposure to aflatoxins is also widespread in Beijing, Taiwan, certain
parts of Africa and other developing areas of the world leading to high risk of liver cancer of
exposed populations. While primary intervention through HBV vaccination has helped to
some extent, secondary intervention strategies through the use of CHL or other drugs such as
oltipraz have greatly helped reduce the risk of disease through various mechanisms discussed
below. Administration of CHL helped reduce AFB1- N7-guanine adducts by as much as
55%. In this aspect CHL has an advantage over other agents such as oltipraz, given its low
cost and high efficacy leading to its easy adoptability by a larger section of at risk human
populations in developing areas (Sudakin 2003; Kensler et al. 2004).
However, there are conflicting reports with regard to the use of chlorophyll or CHL
as chemopreventive agents of choice with some studies pointing to chlorophyll being a better
choice (de Vogel et al. 2005) others CHL (Terwel et al. 1985) and yet others showing both to
be equally effective (Bez et al. 2001). The nature of the carcinogen, system under study and
end points observed may contribute to some of the differences. Again, with respect to CHL,
there are some studies which point not only to the lack of a positive modulatory effect
(Torres-Bezauri et al. 2002) but also to an enhancement of the tumor promotion (Nelson
1992) or increase in mutation frequency (Negraes et al. 2004). In another study, CHL when
administered after or during and after carcinogen exposure (1, 2 dimethyl hydrazine)
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enhanced the number of colon tumors produced in rats. Additionally, in the same study,
when a range of CHL concentrations were administered through drinking water, following
exposure to 1,2 dimethyl hydrazine (DMH) or 2-amino-3-methylimidazo[4,5-f]quinoline
(IQ), the lowest concentration of CHL (0.001%) enhanced the multiplicity of DMH induced
tumors while having no promotion effect on tumors induced by IQ (Dashwood et al. 2001).
Thus, here too the test species involved, carcinogen used, the concentration of CHL
employed, the route of administration and temporal aspects of the exposure protocol may all
be key factors playing an important role in deciding the final role of CHL as an inhibitor or a
potentiator.
Mechanisms of action
Several mechanisms of CHL action have been proposed. By acting as a suicidal
inhibitor, CHL has been shown to bring about non-specific inhibition of CYPs probably
involving destruction of the heme prosthetic group of CYPs (Yun et al. 2005). However,
other investigations involving spectral studies have proposed that the inhibition may be rather
indirect by interacting with NADPH-cytochrome P450 reductase, a rate limiting enzyme in
mixed-function oxygenase system rather than involving any direct interaction with P450.
This interaction may involve a physical interaction of CHL with NADPH-cytochrome P450
reductase preventing docking P450 with or its role as an alternative electron acceptor
interfering with the electron flow from NADPH to P450s (Tachino et al. 1994).
In addition to inhibition of Phase I enzymes, CHL has also been reported to enhance the
expression of Phase II detoxification enzymes. One study revealed that following oral
administration, CHL enhanced the amounts of hepatic glutathione S-transferase in lactating
mice (Singh et al. 1996). Studies on induction of NADPH quinone reductase (NQO1), a
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quintessential Phase II enzymes showed CHL and chlorophylls to be significant inducers of
NQO1 (Fahey et al. 2005).
The most widely accepted mechanism is the role of CHL as an ‘interceptor molecule’
or ‘desmutagen’ wherein CHL in addition to acting as a free radical scavenger also forms
tight molecular complexes with the activated carcinogen preventing it from interacting with
DNA or other cellular macromolecules (molecular trapping). Studies indicate that the
mutagen should possess at least 3 fused rings with some degree of planarity in order to
complex with CHL (Arimoto et al. 1993). Two forces play a key role in complex formation;
van der Walls forces between overlapping ring systems of the mutagen and CHL and ionic or
H bonds between substituents on the mutagen and carboxyl groups of the inhibitor
(Dashwood et al. 1996). In case of BP, hypothetical complexes between CHL and BPDE
(benzo[a]pyrene –trans-7, 8-dihydrodiol-9, 10-epoxide) are thought to be stabilized by
multiple π-π interactions between CHL and BPDE. Following sequestration of the activated
carcinogen (BPDE) by CHL they may be degraded to more hydrophilic tetrols and excreted
(Tachino et al. 1994).
A relatively recent study has also shown the role of CHL as a modulator of
carcinogen uptake and transport. The study examining the effects of a range of CHL
concentrations on the transport of 3 different carcinogens, dibenzo(a,l)pyrene (DBP), 2amino-1-methyl-6-phenylimidaza-[4,5-b]pyridine (PhIP) and AFB1 across Caco-2 cell
monolayers from the apical to the basolateral side found that all concentrations of CHL
reduced the transport of DBP from the apical to the basolateral side though not much effect
was observed on the transport of the other two carcinogens (Mata et al. 2004). Though there
have hardly been any further studies on this aspect of CHL, it may be possible that CHL may
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have a modulatory effect on the intake and transport of BP. CHL has been reported to be a
membrane stabilizer and hence it may be reasonable to make the above assumption (Dhir
1989 ).
As further mechanistic studies and intervention trials are conducted with CHL a
greater number of mechanisms of action and properties of CHL may be unveiled.

2.8 Cytochromes P450 (CYPs)
Most carcinogens (including benzopyrenes) requiring metabolic activation to render
them carcinogenic and are often bioactivated by various members of the cytochrome P450s.
They enzymes possess some of the broadest range of substrate specificities with some being
highly specific (such as those involved in steroid anabolism, mitochondrial and bacterial
P450s) and yet others (such as those involved in oxidation of various substrates) exhibiting a
broad range of catalytic activities (Guengerich 1991; Ioannides 1996; Lewis 2001). These
proteins have been reported to be present in most tissues though mainly concentrated in the
liver (1-2% of an individual hepatocyte by weight) and localized to the endoplasmic
reticulum (12-15%) and to some extent the mitochondria. Some P450s have also been
reported to be translocated outside the plasma membrane where they may have role in
development of immune responses. As of 2005 there were reportedly >4500 named P450
genes (http://drnelson.utmem.edu/CytochromeP450.html).
Structurally, all P450s seem to contain an 8-10-residue signature motif (F G/S x H/R
x C x G/A) with a highly conserved cysteine residue serving as a ligand for a central heme
(Lewis 2001). The central heme is bound to the four pyrrole nitrogens leaving room for two
additional ligands in the axial positions. One of these ligands above the porphyrin plane is
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satisfied by the invariant cysteine and the other ligand below the plane generally being a
hydroxyl group related to a tyrosinyl radical or an exchangeable water molecule (Janig et al.
1984; Porter et al. 1991).
P450s are mainly mixed function oxygenases which require a source of electrons to
function. The electrons which are generally derived from NADPH are delivered to the iron in
the CYP by a flavoprotein, NADPH cytochrome P450 reductase in case of P450s bound to
the endoplasmic reticulum or by another protein, ferrodoxin reductase (adrenodoxin
reductase in case of the adrenals) via an iron-sulfur cluster called ferrodoxin to mitochondrial
P450s (http://drnelson.utmem.edu/CytochromeP450.html). In some less common cases, the
routing of electrons from NADPH is may be carried out through cytochrome b5 and NADPH
cytochrome b5 reductase or microsomal heme oxygenase (Shen et al. 1989).
The CYP superfamily is divided into families, subfamilies and individual genes based
on primary amino acid sequence similarities. P450 protein sequences with ≤ 40% amino acid
sequence identity are grouped into different families. Members within a family are divided
into sub-families and individual genes (http://drnelson.utmem.edu/CytochromeP450.html).
P450s catalyze the metabolism of various endogenous and exogenous substrates. In
general, P450s in most non-animal species seem to be involved chiefly in the metabolism of
endogenous substrates. Different P450 isoforms have been found to be involved in the
biosynthesis and metabolism of steroids, fatty acids, prostaglandins, prostacyclins,
thromboxanes, Vitamin D, bile acids and also in the metabolism of a large number of drugs
(http://medicine.iupui.edu/flockhart/).
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2.8.1 Regulation of CYPs
The amount of functional P450s is subject to considerable inter-individual variation.
Several factors such as the presence of polymorphisms in P450 genes, use of different
nuclear receptors, post-transcriptional (mRNA stabilization) and post-translational (enzyme
stabilization) mechanisms appear to play a role to regulate the abundance and activity of
P450s (Figure 5). Most CYPs however appear to be regulated at the transcriptional level and
many seem to be subject to tissue specific regulation.

Figure 5: Multiple levels in the regulation of P450s. The different levels at which CYPs are
regulated are indicated in red. The specific CYP isoform(s) regulated by the respective
mechanism(s) is indicated below each mechanism.

The most well characterized P450 regulatory mechanisms are with respect to
members of the CYP1 family, regulated by the Ahr-Arnt mechanism (discussed in detail in
the section on BP in 2.4.1).
Transcriptional regulation of the CYP2 family involves various receptors related to
the nuclear receptor family such as the constitutive androstane receptor (CAR) in the case of
CYP2B and the retinoic acid receptor (RAR) in the case of CYP2C (Lewis 2001). In
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addition, members of the CYP2B family are also regulated by protein kinase A (PKA).
mediated phosphorylation (Oesch-Bartlomowicz et al. 2003). The regulation of CYP2A and
CYP2D however, are, mediated by HNF-4 (hepatic nuclear factor-4). The regulation of
alcohol inducible CYP2E1 appears to take place at multiple levels including posttranscriptional and post-translational. Diabetes and fasting appear to have a stabilizing effect
on CYP2E1 mRNA. Presence of chemical inducers also stabilize the protein by preventing
its phosphorylation by PKA and subsequent degradation (Oesch-Bartlomowicz et al. 2003).
CYP3 family members are mainly regulated by members of the orphan nuclear
receptor family, glucocoticoid receptor (GR) and pregnane-X-receptor (PXR).
The CYP 4 family is regulated via another nuclear receptor, peroxisome proliferator
activated receptor (PPAR).
Various other receptors involved in the modulation of different P450s associated with
the metabolism of different endogenous substrates are present in Table 1.
Other mechanisms of regulation include regulation by cyclic AMP (cAMP) in the
case of trophic hormones (Porter et al. 1991), use of cis and trans acting elements along with
co-activator and repressor proteins, cross-talk between specific nuclear receptors (Lewis
2001) and in some rare cases by neonatal imprinting (Porter et al. 1991). In addition, certain
chemicals can inhibit P450s through several mechanisms such as heme ligation, heme adduct
formation, competitive inhibition, formation of reactive intermediates or various
combinations of these and can therefore modulate CYP expression (Lewis 2001).
Polymorphisms in P450s have mostly been addressed in the context of ‘drug
metabolizer’ phenotypes and susceptibility to diseases. However, the underlying cause of
these is the differential expression of the respective P450s caused by the respective
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polymorphisms. For example, *2A and *2B variant alleles of CYP1A1 gene have a T3801C
base change introducing a new MspI restriction site in intron 6. These variant alleles are
associated with enhanced enzyme inducibility and subsequently an elevated risk of smoking
associated lung cancer in Japanese and Caucasian cancer patients (Chowbay et al. 2005). The
P450s form one of the most polymorphic groups of enzymes. A comprehensive list of
different polymorphisms in P450 enzymes can be found at
(http://www.imm.ki.se/CYPalleles/).
In summary, the overall amounts of P450s are governed by the concentration of
inducers and repressors, polymorphisms, and cross-talk with various other receptors, ligands,
proteins, and signaling molecules with other factors within the cell.
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Table 1: List of receptors and factors associated with the induction of some of the P450s
involved with endogenous substrate metabolism
Trophic hormone as
CYP

Receptor/Factor
mediating factor

7

FXR, LXR

11

SF-1

ACTH (adrenals), LH
(testis)
ACTH (adrenals), LH

17

SF-1
(ovary)

19

SF-1, ER

FSH (ovary)

21

SF-1

ACTH (adrenals),

26

RAR, RXR

-

27

VDR

PTH (kidney)

FXR = farnesoid X receptor (down-regulator of bile acid synthesis), LXR = liver X receptor (up-regulator of bile acid synthesis), SF =
steroidogenic factor 1, ER = estrogen receptor, VDR = vitamin D receptor, ACTH = adrenocorticotrophic hormone, LH = lutenizing
hormone, FSH = follicle stimulating hormone, PTH = parathyroid hormone

2.9 Biomarker Concept
Traditional epidemiology has investigated the relationship between exposure and
disease. The extent that identification of preclinical changes was possible assisted the better
understanding of that relationship. Before the introduction of biomarkers the intermediary
steps in the exposure-disease progression were considered to be unknown (a “Black Box”).
The introduction of biomarkers has assisted greatly in the effort to see into the “Black Box.”
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(Hirschhorn et al. 2002; Wogan et al. 2004). The biomarker concept in molecular
epidemiology has been refined significantly since it was articulated by Perera and Weinstein
in 1982 (Perera et al. 1982; Perera et al. 2000) and promises to elucidate a large number of
intermediary steps that have the potential to impact upon risk of disease as depicted in the
schematic representation below.

Biomarkers
of Exposure

Biomarkers
of Disease

▲

▲

Biologically Early
Altered
Exposure ► Internal ► effective ► Biologic ► structure ► Clinical
dose
dose
Effect
& function disease

Biomarkers of
Susceptibility

Schematic representation of the components of the exposure-disease continuum emphasizing
the need for development of biomarkers of human cancer risk at every pathologic stage
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A biomarker is a characteristic that is objectively measured and evaluated as an
indicator of normal biologic processes, pathogenic processes or pharmacological responses to
therapeutic intervention (Srivastava et al. 2002). In order for biomarkers to be valuable they
need to be sensitive, specific and predictable in the manner they change between the normal
and the diseased states.
Human chemical carcinogenesis generally has a long latency. For decades, a
pathology approach has used microscopy of biopsied slides to understand structural changes
underlying the transformation process. Unfortunately, when these discernable or measurable
changes have occurred many molecular changes have also occurred and it is usually too late
for successful intervention (Negm et al. 2002).
Emphasis needs to be on the development of early biological markers of the disease
process prior to the transformation of normal cells. Detecting and understanding these
changes quickly and accurately will he greatly aid in the early detection of cancers. In
addition it will also help shape preventive and therapeutic measures and also predict
prognostic outcomes.
Conventional epidemiology, which draws on casual associations between certain
exposures/lifestyles and risk of certain cancers, requires studies of population risks and may
at best help identify and monitor other individuals or populations at risk; however, it cannot
help early detection of cancer. Recent technological advances have helped in a greater
understanding of the cancer process at the molecular level and in turn has helped develop
biomarkers for early detection and risk assessment of different exposure scenarios
(Srivastava et al. 2002).
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Molecular epidemiology (the use of molecular and biochemical tools to detect early
molecular changes associated with cancer risk) can now be used in conjunction with
conventional epidemiological studies to detect some cancers in their early stages (Weston et
al. 2005). Thus, they are intended to supercede clinical endpoints.

2.9.1 Types of cancer biomarkers
According to schematic representation above there is a hierarchy of biomarkers:
general exposure biomarkers include metabolites in urine, saliva and other body fluids (e.g.,
cotinine and cortisol signaling exposure to nicotine and stress, respectively); biomarkers of
biologically effective dose include carcinogen-protein or carcinogen-DNA adducts derived
from blood (these are surrogates for potential genetic damage in the DNA of target tissues).
BP-DNA adducts have been valuable in the integration of dose and biological propensity of
DNA damage from PAHs (Perera et al. 1982). Exfoliated aflatoxin-guanine adducts in urine
(AFB1-N7-dG) have been identified as a risk factor for hepatocellular cancer in populations
potentially exposed to AFB1 in china and S. Africa (Kensler et al. 2004).
In conjunction with these studies, there is the possibility to assess cancer
susceptibility based on genetic variation. When the continuum of events from exposure to
disease is considered, it should be noted that the contribution from the Human Genome
Project (HGP) has been highly significant in the arena of genetic polymorphisms. Recent
studies have shown that molecular epidemiologic association studies offer a powerful
approach to the identification of genetic variants that influence disease susceptibility
(Hirschhorn et al. 2002; Consortium 2003). Some of these pertain to potential markers of
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susceptibility in the context of a specific exposure scenario, for example: bladder cancer and
the NAT2 genotype in dye workers and in tobacco smokers (Green et al. 2000).
Gene expression patterns have been used to compare different types of tumor,
different tumor grades and tumor response to treatment (Lonning et al. 2005). However, from
the perspective of carcinogenesis, recent studies have identified gene expression patterns
within the continuum of the carcinogenic process. One such study described gene expression
patterns in peripheral white blood cells in response to exposure in tobacco smokers (Lampe
et al. 2004).
In addition to gene expression studies, gene mutation studies have been important
biomarkers that have been used for both understanding etiology (Olivier et al. 2004) and
predicting outcome (Jackson et al. 2003). A prime example is that of p53 mutations. There is
good evidence that exposure to specific agents results in specific or limited types of p53
mutations in certain types of cancer; for example AFB1 and liver cancer, polycyclic aromatic
hydrocarbons and lung cancer, and UV irradiation and skin cancer (Olivier et al. 2004). From
prospective studies of AFB1 related liver cancer, p53 mutations have been identified in
fragments of tumor DNA exfoliated into blood serum before clinical manifestation of
disease. There by providing a biomarker for early liver cancer detection in high AFB1
exposure regions of the world.
Many genes including oncogenes and tumor suppressor genes are regulated by
epigenetic mechanisms. Dysregulation of epigenetic control of various genes such as p15,
p16, APC and VHL have been observed to occur early on in several cancers (Negm et al.
2002).
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Other penitential biomarkers include measurement of chromosomal aberrations, point
mutations and loss of heterozygosity in DNA from various body fluids of cancerous patients.
Presence of anti-apoptotic proteins in the urine of patients with recurrent bladder cancer has
been reported and has been found to be a useful biomarker (Smith et al. 2001).

2.9.2 Challenges in using biomarkers
In order for biomarkers to be used efficiently and reliably they will need to be highly
sensitive and specific. Though there has been significant progress in the field of cancer
biomarker research over the last two decades it has still not reached a level of confidence for
application in the clinical setting, and validation studies are required. Some of the biomarkers
currently in use such as prostrate specific antigen (PSA) for prostrate cancer, CA125 for
ovarian cancer are not very specific for their respective cancers. In addition, in this time of
rapidly advancing technological developments, there is a need for more effective as well as
novel cancer biomarkers.
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2.10 Statement of the problem
Benzopyrenes, a class ubiquitous environmental contaminants are procarcinogens.
Due to their widespread distribution, alternative strategies such as the use of
chemopreventive measures to mitigate some of the genetic damage caused by these
chemicals may form a practical approach. This study was designed to seek biomarkers of BP
exposure (using microarrays) which could subsequently form targets for chemopreventive
intervention. CHL, a water soluble metalloporphyrin was used as a chemopreventive agent in
all these studies. Also, since benzopyrenes are procarcinogens requiring metabolic activation
by CYP1 enzymes for their conversion to DNA damaging metabolites, the effect of CHL on
mitigating the expression of CYP1 enzymes, in addition to their efficacy in preventing the
interaction of the activated BP metabolites with cellular macromolecules such as DNA as
measured by RT-PCR and BP-DNA adduct analysis, respectively was determined. B[e]P, a
structural isomer of BP which has been reported to be weakly carcinogenic was also
examined in parallel with BP (both in the absence and presence of CHL) to induce CYP1
gene expression as well as cause DNA adduct formation. In addition, MCF-7, a malignantly
transformed breast cell line was observed in parallel with NHMECs across different CHL
treatments and concentrations to examine if their responses parallel those of normal cells and
in turn whether they can be used as a surrogate to normal cells in studying carcinogenic
stress.
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3.0 MATERIALS AND METHODS

Most experiments in this study were carried out on a panel of primary NHMECs
developed from breast tissue discarded at reduction mammoplasty. In order to compare the
responses of cancerous cells, a breast cancer cell line, MCF-7 was used in parallel with
NHMEC(s) for some of the studies. Genome-wide changes in gene expression patterns were
initially observed in a panel of 6 NHMECs. Subsequently, gene expression patterns of
CYP1A1 and CYP1B1, two key BP metabolizing enzymes as well as the level of BP-DNA
adducts was observed in a panel of 20 NHMECs. For studies on the comparison CYP1A1,
CYP1B1 gene expression and the extent of DNA adducts on treatment of cells with BP or
B[e]P, 2NHMECs (M98025 and M98015) were used. Studies for comparison of normal cells
with malignantly transformed cells were carried out on a NHMEC strain (M00012) and the
cancerous cell line MCF-7 over a range of CHL concentrations and treatments. An overview
of the different experiments carried out in this study is shown in Table 2.

3.1 Breast tissue
Breast tissues from otherwise healthy women undergoing reduction mammoplasty
were obtained from the Cooperative Human Tissue Network (CHTN) sponsored by the
National Cancer Institute (NCI) and National Disease Registry Interchange (NDRI).
Information on age, ethnicity of donors and a corresponding pathology report were obtained
without personal identifiers. Since tissue samples were provided without personal identifiers
the study was granted a waiver by the Human Studies Review Board at NIOSH.
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3.2 Development of NHMEC strains
NHMECs were isolated from the breast tissues by a process involving a combination
of mechanical disruption, enzymatic digestion and filtration as described (Stampfer et al.
1980) with slight modifications. Briefly, stromal and epithelial tissue masses (following
removal of fat deposits (by dissection) were minced to 1-2 cm pieces, filled into 50 ml
conical tubes up to 1/3rd the capacity and incubated overnight at 370C, on a wave mixer with
constant shaking with Tissue Digestion mix (Appendix). Following partial digestion the
following day, the tubes were spun (250g, 10min in a swinging bucket centrifuge), the
supernatant removed and the tissue pellet resuspended in fresh Tissue Digestion mix and
incubated for another 24-48h to ensure complete tissue digestion. Complete tissue digestion
was ascertained by observing for organoids (cell clumps) under 40X and 60X objectives of
an Olympus IX70 Inverted Fluorescent light microscope. Completely digested pellets were
pooled together (typically 4 tubes into1) and resuspended in 5 ml freezing media (Appendix).
The resuspended pellets were then filtered through a 150 μm nylon filter and the flow
through refiltered through a 90 μm nylon filter. The organoids retained on the 150 μm nylon
filter were resuspended in a small volume of freezing media (Appendix) to constitute the 150
μm ductal pool consisting mainly of a population of epithelial cells. Similarly, the organoids
on the 90 μm filter were resuspended in a small volume of freezing media to constitute the 90
μm fraction consisting of some small epithelial clumps. The 150 μm fraction, 90 μm fraction
and the filtrate obtained after retention of the 90 μm fraction were all separately aliquoted to
cryogenic vials frozen in isopropanol containers at -800C overnight and then archived in
liquid nitrogen until needed.
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3.3 Cell culture
NHMECs were grown and sub-cultured up to passage 6. The 150 μm organoids were
seeded with a sterile Pasteur pipette to collagen treated flasks, allowed to stand for about 5
minutes and then supplemented with reconstituted serum-free mammary epithelial medium
(MEBM; Clonetics™, Wakersville, MD) supplemented with manufacturer supplied
Singlequots™ (gentamycin sulfate-amphothericin B, recombinant human epidermal growth
factor, bovine insulin, bovine pituitary extract and hydrocortisone). Cell migration from the
organoids was generally observed 24-48h after seeding. Cells were allowed to reach 60-70%
confluency before they were sub-cultured. Cells were maintained in MEBM mammary
epithelial medium at 370C, 5% CO2 and 95% relative humidity. NHMECs are adherent cells
and were sub-cultured by trypsinization. Cells at 60-70% confluency were washed once with
1X PBS following removal of media, incubated with 0.025% Trypsin-EDTA (Clonetics™,
Wakersville, MD) at 2 ml Trypsin-EDTA/25cm2 growth area of the flask and then incubated
at 370C for 2-3 min till ≥ 90% of the cells detached from the flask and appeared rounded
when viewed under the microscope. At this stage the flask was gently rapped and the
Trypsin-EDTA neutralized with Trypsin Neutralizing Solution (TNS) at 4 ml TNS/25cm2
growth area of the flask and the detached cells were transferred to a 50 ml conical tube. The
residual cells in the flask were collected by rinsing the flask with 1X PBS. The cells were
centrifuged at 150g for 6min in a fixed angle centrifuge. The supernatant was aspirated, the
cells washed with 1X PBS and cell pellet finally resuspended in MEBM mammary epithelial
media. The suspended cells were then seeded into new flasks at 10,000 cells/cm2 and
maintained in MEBM mammary epithelial medium. In this manner, cells were passaged up
to passage 6. MCF-7 cells were from ATCC and were grown, passaged and maintained in a
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manner similar to the NHMECs. MCF-7 cells were grown and maintained in MCF-7 media
(Appendix).

3.4 Cell treatments
All treatments were carried out on a uniform population of ~ 70% confluent cells at
passage 6. The concentration of BP in all experiments was 4 μM. The concentration of CHL
used was 5 μM for all experiments except for experiments involving a comparison of MCF-7
cells with a NHMEC across a range of CHL concentrations. For these CHL dose response
studies, CHL was used at a concentration of 2 μM, 3 μM, 4 μM, 8 μM and 16 μM. In all
these experiments the concentration of BP and CHL used were decided based on preliminary
cytotoxicity assays. For studies on comparison of BP and B[e]P the concentration of B[e]P
used was also 4 μM in order to have a direct comparison with the effects of BP and was also
dissolved in the same solvent as BP. BP was initially dissolved in acetone to obtain a 10 mM
solution and subsequently diluted to 4 mM with absolute ethanol. The 4 mM solution was
stored in amber vials shielded from light at -200C until needed. Nuclease free water served as
the solvent for CHL. For treatment of MCF-7 and NHMECs with 5 μM CHL an initial stock
solution of 5 mM was prepared. For the CHL dose response study, 2 mM, 3 mM, 4 mM, 8
mM and 16 mM solutions were prepared. All CHL solutions were prepared fresh just before
use and shielded from light. These stock solutions of BP and CHL respectively were later
diluted 1000 fold in MEBM mammary epithelial medium just prior to treatment of cells to
obtain the desired micromolar concentrations. Acetone: ethanol (2:3) at 1:1000 dilution used
as a solvent for BP served as the vehicle control. All treatments were carried out in duplicate
(n = 2).
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The treatment protocol of 20 NHMECs and MCF-7 is detailed in Table 3. The treatment
protocol for comparison of NHMECs on treatment with BP or B[e]P in the absence or
presence of CHL is detailed in Table 4. The treatment protocol for the CHL dose response
study comparing MCF-7 and a NHMEC (M00012) across a range of CHL concentrations is
presented in Table 5.

3.5 Expression analysis
Analysis of genome-wide changes in gene expression patterns following exposure of
NHMECs to BP in the absence or presence of CHL was carried out using microarrays.
Subsequently, confirmation of gene expression patterns for a selected subset of genes which
appeared altered on microarrays was carried out through real time polymerase chain reaction
(RT-PCR). The magnitude and patterns of expression of CYP1A1 and CYP1B1, the main
CYP isoforms known to be involved in the metabolism of BP/B[e]P was also carried out
through RT-PCR.

3.5.1 Microarray analysis
Arrays
Human genome U133A (HG-U133A) arrays containing 22,283 probe sets
representing ~ 14,500 genes were purchased from Affymetrix (Affymetrix, Santa Clara, CA).
The sequences used in the design of these arrays were derived from GenBank, dbEST, and
RefSeq. These arrays form a part of the HG-U133 set which consists of 2 arrays (HG-U133A
and HG-U133B) and altogether consists of almost 45,000 probe sets representing
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approximately 33,000 well-substantiated human genes. HG-U133B mostly consists of ESTs
and was therefore not used in this study.
Target generation
For microarray analysis due to considerations of cost and time involved only 3
treatment groups (solvent control (SC), BP, and pre CHL + post co-treatment) were
considered across 6 NHMEC strains (M98035, M99005, M98015, M98025, M99025 and
M99016).
Total RNA isolation
Total RNA following treatment of cells was isolated using RNeasy kit (Qiagen, Valencia,
CA) according to manufacturer’s instructions. Cells following treatment were washed with
1X PBS, lysed in a chaotropic buffer containing guanidine isothiocyanate and homogenized
in a spin column (Qiashredder) to shear high molecular weight DNA. The lysate containing
total RNA was bound to a silica gel based membrane (RNeasy column) and the contaminants
washed away using the manufacturer supplied wash buffers (RWE and RPE). Finally the
bound total RNA was eluted out using RNAse free water.
cDNA synthesis
12 μg of total RNA (260:280 ratio >1.9 and clear, non-smearing rRNA bands on agarose gel)
were used for synthesis of double stranded cDNA using T7-oligo(dT) promoter primer kit
(Affymetrix, Santa Clara, CA) and SuperScript Double-Stranded cDNA Synthesis kit,
(Invitrogen

Life Technologies, Carlsbad, CA) as per manufacturer’s instructions. The

generated double stranded cDNA was cleaned by phenol-chloroform extraction using Phase
Lock Gels (PLG) and finally ethanol precipitated. The precipitated cDNA was dissolved in
12.0 μl nuclease free water.
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cRNA synthesis
A ‘one cycle’ target labeling assay was used for generation of labeled target. 6.0 μl of
cleaned cDNA was used for the generation of biotin labeled complementary RNA (cRNA)
target for hybridization on to HG-U133A arrays using the Gene Chip IVT Labeling Kit
(Affymetrix, Santa Clara, CA). The generated cRNA was purified using RNeasy Kit (Qiagen,
Valencia, CA) as per manufacturer’s protocol. The cleaned cRNA was subsequently
quantified using a Beckman DU 7500 UV/VIS spectrophotometer (Beckman Coulter, Inc.,
Fullerton, CA) to determine the yield and quality of the generated cRNA. An adjusted cRNA
yield was calculated using the formula below for further down-stream processing.
Adjusted cRNA yield = RNAivt – (Total RNA) (y)
RNAivt = amount of cRNA obtained following spectrophotometric analysis
Total RNA = starting amount of total RNA used for cDNA synthesis
y = fraction of the purified cDNA used for cRNA synthesis
The cRNA was subsequently fragmented to 35-200nt bases (940C, 35 min) prior to
hybridization on to the arrays by metal induced hydrolysis using a 5X RNA fragmentation
buffer (Appendix).
Hybridization
15 μg of fragmented cRNA were used for hybridization on to ‘standard’ Hu-Gene
133A arrays. The efficiency of target hybridization was assessed by incorporating pre-mixed,
staggered concentrations of biotin labeled cRNA transcripts for three bacterial genes of the
biotin synthesis pathway (bioB, bioC, bioD) and one bacteriophage gene for recombinase
(cre) at staggered concentrations of 1.5 pM, 5 pM, 25 pM and 100 pM, respectively in a
hybridization cocktail. A B2 oligo used as a positive hybridization control by the analysis
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software to place a grid over the scanned image and demarcate the probe area was also
spiked into the hybridization cocktail. The remaining components spiked into the
hybridization cocktail included herring sperm DNA, acetylated BSA, hybridization buffer
and DMSO (Affymetrix 2004). The cocktail was heated to 990C for 5 min prior to
hybridization. The arrays with the hybridization cocktail were then incubated in a rotisserie
oven at 450C for 16h with constant rotation (60 rpm).
Washing, staining and scanning
The hybridized arrays were subsequently washed and stained on the GeneChip
Fluidics Station 400 (Affymetrix, Santa Clara, CA) using Eu-GE-W2v4 protocol of
Microarray Suite (MAS) 5.0 (Affymetrix 2004). A signal amplification protocol consisting of
first using streptavidin phycoerythroprotein (SAPE) followed by a biotinylated antibody to
SAPE and then SAPE again was used as opposed to a single stain protocol. Following
washing and staining the arrays were scanned with an argon-ion laser on the HP GeneArray
2500 Scanner (Hewlett Packard, Palo Alto, CA).
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Data analysis
The scanning of arrays generated image files (.dat files) (Figure 6).

Figure 6: Representative scanned
image obtained following scanning
of arrays.

These .dat files were analyzed using MAS 5.0 (Affymetrix, Santa Clara, CA) to
generate .cel files (with individual cell intensities), .chp files (with the analysis of cell
intensities) and .rpt files (report files with an overview of various quality control parameters
for each array/hybridization). Initially an ‘absolute analysis’ was conducted to compute
absolute signal intensities of the SC as well as treated groups (BP and pre CHL + post cotreatment). ‘Absolute analysis’ involves analysis of each of the individual arrays to determine
the presence or absence of a particular transcript (Detection call), measure their relative
abundance (Signal) and also provide a ‘Detection p-value’ evaluated against a user defined
cut-off to determine the Detection call. Two algorithms, a detection algorithm and a signal
algorithm are employed to achieve this.
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Subsequently, a ‘comparison analysis’ comparing the fold change (FC) of the treated
groups over the SC (BP versus SC and pre CHL + co-treatment versus SC) was also
conducted. A ‘change algorithm’ which defines the nature of change (increase, decrease or
no change) in expression trends of the experimental array as compared to its counterpart
baseline array and another algorithm which provides a quantitative measure of the
magnitude of change in terms of signal log ratio (SLR) are used for comparison analysis.
In this study, only probe sets having a Present call (P) and a FC ~3.0 or greater (SLR
≥1.5) for up- regulated genes and SLR≥-1.5 for down-regulated genes in both replicates in at
least one of the 6 NHMECs were considered altered. Various quality control parameters such
as background, noise, 3'/5' GAPDH and β-Actin ratios, and % Present calls (between
replicates) were examined in the .rpt files.
Graphical representation of all the altered genes were generated using Cluster and
Tree View software (http://rana.lbl.gov/EisenSoftware.htm) using the average-linkage
method (Sokal et al. 1958).
To identify common patterns of gene expression patterns across cell strains following
different treatments ‘coefficient of correlation clustering’ was conducted using Micro DB 3.0
and Data Mining Tool (DMT) 3.0 (Affymetrix, Santa Clara, CA). In the ‘correlation of
coefficient’ clustering, ‘seeding’, a pre-clustering process involving initial grouping of a
small subset of genes with similar expression patterns to generate a ‘seed’ is first carried out
with a user specified correlation coefficient threshold. Subsequently, a correlation coefficient
threshold to assign probe sets to a particular ‘seed’ in order to create a ‘cluster’ is also
defined (Affymetrix 2001). In this study, the correlation threshold of forming ‘seeds’ and
assignment of genes to respective clusters were both set at 0.90. Clustering was carried out to
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first find the genes common across all 6 cell strains on comparison of treated groups versus
SC (BP versus SC and pre CHL + co versus SC). Only genes with a Present call (P) in both
the replicates were used for the preliminary clustering. Subsequently, an unpaired, one-sided
T test was carried out on above set of genes common to all 6 cell strains to find genes
significantly altered due to respective treatment (p < 0.05) and also determine the direction of
change (‘up’ or ‘down’). Gene expression ‘cluster maps’ were finally generated from the
above subset of statistically significantly altered genes exhibiting particular expression
pattern.
Due to the importance of host immune responses in better tackling genotoxic insults,
cross-talks between immune response genes altered by SLR ≥ 1.5 in at least one of the 6
NHMECs by the respective comparisons (BP versus SC and pre CHL + co versus SC) as
well as any possible statistically significant associations of the altered genes with any of the
presently well known and characterized biological pathways in GenMAPP, PharmGKB,
KEGG and BioCarta was carried out using Pathway Studio v1.1 software (Ariadne
Genomics, Rockville, MD) and ArrayXPath software
(http://www.snubi.org/software/ArrayXPath), respectively.
Pathway Studio relies on a proprietary ResNet database to query nearly 500,000+
functional relationships distilled from the entire PubMed and 43 full text journals to
automatically extract information from scientific literature, and works with leading public
and commercial databases of signaling and biochemical pathways, to construct cross-talks
between the input genes/ proteins (http://www.ariadnegenomics.com). Initially, using
Pathway Studio v1.1 all possible interactions of the altered immune response genes with all
other processes, entities and proteins in the cell was deciphered. Later, ‘shortest path’
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interactions were sought. Finally, only direct interactions, if any, between genes altered by
the respective treatments were deciphered.
ArrayXPath is web-based software for mapping and visualization of microarray geneexpression data in the context of integrated biological pathway resources. A total of 45
pathways in GenMAPP pathways, 9 pathways PharmGKB pathways, 70 pathways in KEGG
pathways and 346 pathways in Biocarta are queried by ArrayXPath to calculate associations
of input genes with the respective pathways. A statistically significant association of the
input gene(s) with alteration of the respective pathway is defined by a ‘p’ value
(http://www.snubi.org/software/ArrayXPath). For genes involved in more than one pathway,
a second p value (in this case designated as q value) accounts for the multiple-comparison. In
this analysis, both ‘p’ and ‘q’ values were set at ≤ 0.05.

3.5.2 RT-PCR
Confirmation of gene expression on microarray was carried out through RT-PCR
using ‘SYBR green chemistry’ for a selected sub-set of probes altered by SLR ≥ 1.5 in at
least one of the 6 NHMEC strains. 1μg of total RNA isolated from 3 treatment groups (SC,
BP and Pre CHL + post co-treatment) using RNeasy kit (Qiagen, Valencia, CA) was reverse
transcribed to single stranded cDNA using Advantage RT PCR kit (BD Biosciences, Palo
Alto, CA) as per manufacturer’s instructions
Primers for these genes were designed using Primer Express v1.5 (PE Applied
Biosystems, Foster City, CA), got synthesized from Sigma–Genosys (Wodlands, TX) and
used at 50 pmol concentration of each primer in a 25 μl reaction mix with SYBR Green
Universal PCR Master Mix (Applied Biosystems, Foster City, CA). Quantitation was carried
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out using a standard 96-well block on the 7900HT Fast Real-Time PCR System preloaded
SDS software v2.2.2 (Applied Biosystems, Foster City, CA). Each sample was assayed in
duplicate and their expression normalized to that of GAPDH using the 2-∆∆CT method (Livak
et al. 2001). The specificity of the generated product was confirmed by looking for a single
specific product on ‘Amplify’ software v1.2β (University of Wisconsin, Genetics, Madison)
prior to RT-PCR as well as going in for dissociation curves at the end of the run.
CYP1A1 and CYP1B1 quantitation across the panel of 20 NHMECs and MCF-7 cells
for all treatment groups was carried out using ‘Taqman chemistry’. The expression analysis
across the 20 NHMECs (on treatment with BP in the absence or presence of CHL as detailed
in Table 3) and 2 NHMECs (on treatment with BP/B[e]P in the absence or presence of CHL
as detailed in Table 4) were carried out on the ABI7700 Sequence Detection System (PE
Applied Biosystems, Foster City, CA). CYP1A1 and CYP1B1 quantitation in MCF-7 cells
and M00012 across different CHL concentrations (as detailed in Table 5) and in MCF-7 cells
across different CHL treatments (as detailed in Table 3) was carried out on the ABI 7900HT
Fast Real-Time PCR System (PE Applied Biosystems, Foster City, CA) using ‘Taqman
chemistry’. 1.0 μg of total RNA (RNeasy kit; Qiagen, Valencia, CA) from each of the treated
groups was used for cDNA synthesis. Single stranded cDNA (Advantage RT PCR kit; BD
Biosciences, Palo Alto, CA) was used as template in a 50µl reaction mix consisting of 2X
Taqman Universal PCR Master Mix and Taqman® Gene Expression Assay primers and
probes for CYP1A1 (Hs00153120_ml) or CYP1B1 (Hs00164383_ml) (Applied Biosystems,
Foster City, CA). Each sample was assayed in duplicate and their expression normalized to
that of GAPDH (Hs99999905_ml; Applied Biosystems, Foster City, CA) using the 2-∆∆CT
method (Livak et al. 2001).
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3.6 Adduct analysis
BP-DNA adducts formed on treatment of 20 NHMECs as well as MCF-7 cells with
BP in the absence or presence of CHL was determined through a chemiluminiscence
immunoassay (CIA). B[e]P-DNA adducts formed on treatment of 2 NHMEC strains with
B[e]P in the absence or presence of CHL was analyzed through synchronous fluorescence
spectrometry (SFS).

3.6.1 DNA extraction
DNA was extracted using a non-organic extraction protocol (Laird et al. 1991).
Following treatment, cells were washed with 1X PBS, incubated in a lysis buffer (100 mM
Tris pH 8.5, 5 mM EDTA, 0.2% SDS, 200 mM NaCl and 100 µg/ml Proteinase K) at 370C
for 3h and the DNA precipitated with an equal volume of isopropanol. The precipitated DNA
was washed twice with 70% ethanol and then dissolved in nuclease free water.

3.6.2 BP-DNA (BPdG) adduct analysis
BPdG adducts were measured by a chemiluminiscence immunoassay (CIA) using
antiserum elicited against DNA modified with (±)-7β,8α, dihydroxy 9α,10α-epoxy-7,8,9,10tetrahydrobenzo[α]pyrene (BPDE) (8). Briefly, sonicated (20s, 20% amplitude, Ultrasonic
Processor, Sonics & Materials, Inc, Newton, CT) and heat denatured (950C, 4min and then
cooled on ice) sample DNA or serially diluted standard BPDE-DNA (1.0 BPdG adduct/106
nucleotides) was mixed with an equal volume of rabbit anti-BPDE antiserum (1:3000000 in
0.25% casein prepared in phosphate buffered saline containing 0.05% Tween-20 (PBST)),
incubated at 370C for 15 min and added to wells of 96-well high binding LIA microtiter
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plates (Greiner Labortechnik, FRG) coated with highly modified BPDE-DNA or calf thymus
DNA. These plates were prepared by coating with 100 pg of highly modified, sonicated
BPDE-DNA (0.33% modified) or non-adducted calf thymus DNA in 0.1ml Reactibind
solution (Pierce Biotechnology, Inc., Rockford, IL) for 48h following which they were
washed with PBST containing 0.05% sodium azide and stored at -200C until used. The plates
along with the sample or standard DNA were incubated at 370C for 90 min, washed with
PBST, incubated with streptavidin alkaline phosphatase (Avidx-AP: 1:5000, 60 min; Applied
Biosystems, Foster City, CA) prepared in 0.25% casein, washed again with PBST and Tris
buffer (20 mM Tris, 1mM MgCl2, pH 9.5) before finally incubating with CDP-Star solution
containing Emerald II enhancer (Applied Biosystems, Foster City, CA). The plates were
incubated overnight at 40C and the luminescence measured at 542 nm on TR717 Microplate
Luminometer (Applied Biosystems, Foster City, CA) on the following day after equilibration
of the plates to room temperature. All samples were assayed in triplicate experimental wells
and two separate CIAs.

3.6.3 B[e]P-DNA adduct analysis
DNA extracted using a non-organic protocol as detailed above were assayed for
B[e]P-DNA adducts using synchronous fluorescence spectrometry (SFS). 100 μg of DNA
was acid hydrolyzed (900C, 3h), extracted three times with equal volumes of water-saturated
isoamyl alcohol and then resuspended in 600 μl HPLC grade water. Benzo(a)pyrene-r-7, t-8,
c-9, t-10-tetrahydrotetrol (+/1) was used to generate a standard curve. Synchronous spectra
were obtained by driving the excitation and emission monochromators simultaneously with a
wavelength difference of 34 nm. Fluorescent emission was obtained at emission wavelength
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of 380 nm (345 nm excitation wavelength). All measurements were carried out on a Perkin
Elmer LS50B spectrophotometer (Perkin Elmer Corp., Rockville, MD) loaded with WinLab
FL software.

3.7 Statistical correlations
Pearson correlation coefficients between the extent of expression of CYP1A1 and
CYP1B1 on gene-chip (GC) versus RT-PCR as well as correlation coefficients between
CYP1A1 and CYP1B1 expression and levels of carcinogen-DNA adducts on treatment of
NHMECs or MCF-7 cells with BP or B[e]P in the absence or presence of CHL were
determined using Excel (Saunders et al. 1994). Positive values indicate an increase in the
value of the dependent variable with a corresponding increase in the independent variable
and vice versa.
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Table 2: Details of different experiments carried out in the present study
Experiment

Number and

Cell strains used

type of cell

Treatments
used

strains used
1. Microarray
analysis

6 NHMECs

M98035, M99005, M98015,
M98025, M99025, M99016

1, 2 and 5 as
detailed in
Table 3

2. RT-PCR and DNA
adduct analysis
a. On treatment with

20 NHMECs

BP ± CHL

M98026, M98019, M98014,

1, 2, 3, 4

M98011, M99021, M99006,

and 5 as

M99025, M0004, M98025,

detailed in

M98035, M99005, M99003,

Table 3

M00012, M99004, M98016,
M99015, M98030, M98015,
M98013, M99016
b. On treatment with

2 NHMECs

M98015 and M98025

BP or B[e]P ± CHL

1, 2, 3, 4
and 5 as
detailed in
Table 4

c. On comparison of

20 NHMECs

The same 20 NHMECs

1, 2, 3, 4

a NHMEC versus a

and MCF-7

mentioned above and MCF-7

and 5 as

(cancerous cell line)

detailed in

cancerous cell line
on treatment with BP

Table 3

± CHL
d. On treatment with

1 NHMEC

M00012 (NHMEC strain)

1, 2, 3, 4, 5,

BP ± a range of CHL

strain and

and MCF-7 (cancerous cell

6 and 7 as

concentrations

MCF-7

line)

detailed in
Table 5

58

Table 3: NHMECs and MCF-7 cells treatment protocol

Treatment
1. Control vehicle

Treatment protocol
-

Acetone: ethanol (1:1000)-24h

2. BP alone (BP)

-

BP (4 μM)-24h

3. CHL + BP

-

[CHL (5 μM) + BP (4 μM)]-24h

(SC)

(co-treatment)
4. Pre CHL + post

CHL (5 μM)-24h

+

BP (4 μM)-24h

CHL (5 μM)-24h

+

[CHL (5 μM) + BP (4 μM)]-24h

BP treatment
5. Pre CHL + post
co-treatment
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Table 4: Treatment protocol for the comparison of BP and B[e]P across 2 NHMECs
(M98015 and M98025)

Treatment

Treatment protocol

1. Control vehicle (SC)

-

Acetone: ethanol (1:1000)-24h

2. BP or B[e]P alone

-

BP or B[e]P (4 μM)-24h

3. CHL + BP or B[e]P

-

[CHL (5 μM) + BP or B[e]P(4

(co-treatment)
4. Pre CHL + post BP

μM)]-24h
CHL (5 μM)-24h

+

BP or B[e]P (4 μM)-24h

CHL (5 μM)-24h

+

[CHL (5 μM) + BP or B[e]P (4

or B[e]P treatment
5. Pre CHL + post BP
co-treatment or post

μM)]-24h

B[e]P co-treatment
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Table 5: Treatment protocol for the CHL dose response study comparing MCF-7 and
an NHMEC (M00012) across a range of CHL concentrations

Treatment

Treatment protocol

1. Control vehicle (SC)

-

Acetone: ethanol (1:1000)-24h

2. BP alone (BP)

-

BP (4 μM)-24h

3. Pre 2 μM CHL +

CHL (2 μM)-24h

+

[CHL (2 μM) + BP (4 μM)]-24h

CHL (3 μM)-24h

+

[CHL (3 μM) + BP (4 μM)]-24h

CHL (4 μM)-24h

+

[CHL (4 μM) + BP (4 μM)]-24h

CHL (8 μM)-24h

+

[CHL (8 μM) + BP (4 μM)]-24h

CHL (16 μM)-24h

+

[CHL (16 μM) + BP (4 μM)]-24h

post BP + 2 μM
CHL co-treatment)
4. Pre 3 μM CHL +
post BP + 3 μM
CHL (co-treatment)
5. Pre 4 μM CHL +
post BP + 4 μM
CHL (co-treatment)
6. 8 μM CHL + post
BP + 8 μM CHL
(co-treatment)
7. Pre 16 μM CHL +
post BP + 16 μM
CHL (co-treatment)
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4.0 RESULTS

4.1 Gene expression by microarray
The expression of a multitude of genes involved in diverse cellular functions was
altered by BP. The expression patterns of all the 22,283 probe sets (14,500 genes) on HuGene 133A array in each of the 6 NHMEC strains on treatment with BP alone or in the
presence of CHL (pre CHL + post co-treatment) are presented in Figure 7. The figure
depicts a plot of the signal from each of the 22,283 probe sets for each of the respective
treatment replicates versus the corresponding FC for those probe sets. It provides an
overview of the scatter of expression patterns across cell strains and treatments. Each cell
strain exhibited similar expression patterns for some of the probe sets yet unique expression
patterns for others. The scatter plot also shows that for some probe sets while the signal
may be low the overall FC compared to SC could be high and vice versa. While the
expression of majority of the genes across most cell strains exhibited variation within 2-3
fold, there clearly appeared to be outliers which were treatment as well as cell strain
specific. Of these probe sets, only those altered by a FC of ~3.0 (SLR≥ 1.5) in both the
replicates upon comparison analysis of a respective treatment versus SC were considered
altered. A complete list of all genes altered by SLR ≥ 1.5 in at least one of the 6 NHMECs
on comparison of BP treated as well as pre CHL + post co-treated cells versus SC can be
found in Tables A, B, C , D and E at (http://www.cdc.gov/niosh/ext-suppmat/MTP/index.htm). Genes of the biotin synthesis pathway, bioB, bioC, bioD and the
bacteriophage gene, cre spiked in the hybridized cocktail as hybridization controls were all
detected on the arrays with signals in increasing order, as expected. Human GAPDH and
Actin, house keeping genes were also detected. The average background, noise, percentage
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BP versus control vehicle

Pre CHL + co-treated versus control vehicle

M98035

M99005

M98015

M98025

M99025

M99016

Signal

Signal

Figure 7: ‘Fold change’ scatter plots showing expression patterns of all the 22,283 probe sets on HuGene133A arrays on comparison of treated groups versus control vehicle. More details in the text.
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of genes present, absent and average signal intensities were also examined for each of the
arrays.
A total of 49 genes (0.38%) were altered in at least one of the 6 NHMEC strains on
comparison of BP treated cells with SC when analyzed by MAS 5.0. Of these 43 were upregulated and only 6 were down-regulated. Only CYP1B1 exhibited consistent upregulation by SLR ≥ 1.5 in all 6 cell strains. ALDH1A3 (probe ID 222168_at) showed upregulation in 4 cell strains. All other genes were up-regulated in less than 4 cell strains. All
down-regulated genes were from only one cell strain, M99016 and no gene was
consistently down–regulated by SLR≥ 1.5 in all the cell strains. IL1B and SECTM1 were
immune response genes consistently up-regulated by BP in most individuals with M99016
exhibiting the greatest expression with SLR ≥ 1.5. Both the above genes also exhibited the
greatest expression in M99016 on pre-treatment with CHL followed by co-treatment and
were, therefore, represented in the list of genes up-regulated by BP as well as pre CHL +
post co-treatment. Overall, genes altered included those involved with xenobiotic
metabolism, cell signaling, cell motility, cell proliferation, cellular transcription,
metabolism, immune responses and other processes.
A total of 125 genes (0.86%) were altered in at least one of the 6 NHMEC strains
on comparison of pre CHL + post co-treated cells with SC when analyzed by MAS 5.0. Of
these 103 were up-regulated and 22 down-regulated. Again, only CYP1B1 was consistently
up-regulated by SLR ≥ 1.5 in all but one cell strain. No gene was consistently downregulated by SLR ≥ 1.5 in all cell strains. Gene categories modulated included mainly those
altered by BP treatment in addition to genes involved in cell cycle control, apoptosis, DNA
repair and various other cellular processes such as neurogenesis, gene regulation, and
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hormonal metabolism. A graphical display of all the altered genes generated using Cluster
and Tree View (http://rana.lbl.gov/EisenSoftware.htm) according to the average linkage
method (Sokal et al. 1958) is presented in Figure 8.
As per DMT 3.0 analysis a total of 5 different expression clusters were obtained on
clustering of genes altered by comparison of treated groups versus SC (Figure 9). One
cluster each was generated on clustering of genes significantly up-regulated and downregulated by BP as well as genes significantly down-regulated by pre treatment with CHL
followed by co-treatment. However, two different expression clusters were generated for
genes significantly up-regulated by pre CHL + post co-treatment. In all cases, the
correlation of the altered genes belonging to the respective cluster pattern was 0.99. A
complete list of all the genes following the respective cluster patterns can be found in
Tables G, H, I and J at (http://www.cdc.gov/niosh/ext-supp-mat/MTP/index.htm). More
details of the characteristics of the genes used for the ‘correlation coefficient’ clustering are
displayed in Table 6.
Given the importance of immune responses in parallel with other cellular
mechanisms such as detoxication and repair mechanisms to combat toxic stress, immune
response genes altered by SLR ≥ 1.5 in at least one of the 6 NHMECs in both the replicates
upon comparison analysis of a respective treatment versus SC by MAS 5.0 were analyzed
separately. Any interactions and cross-talks between the significantly altered immune
response genes as well as other cellular proteins were analyzed. A total of only 5 immune
response genes were altered by SLR ≥ 1.5 on comparison of BP treated cells versus SC of
which 4 were up-regulated and only 1 was down-regulated by SLR ≥ 1.5 in at least one of
the 6 NHMEC strains. The expression of 24 genes was altered by the synergistic
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BP versus
control vehicle

Pre CHL + cotreatment versus
control vehicle

Genes altered (SLR
≥1.5) by BP versus
control vehicle

Genes altered (SLR
≥1.5) by pre CHL +
co-treatment versus
control vehicle

Figure 8: Graphical display (generated using Cluster and Tree View software) of all genes
altered by SLR ≥ 1.5 on Hu-Gene 133A arrays in at least one of the 6 NHMECs on
treatment of cells with BP or pre CHL + co-treatment. A total of 49 genes were altered (up
or down regulated) on treatment with BP alone and 125 on pre treatment with CHL
followed by co-treatment. Though the gene names are not decipherable in the figure above
due to the number of genes involved, a complete listing of all the above genes along with
their corresponding FCs can be found at (http://www.cdc.gov/niosh/ext-suppmat/MTP/index.htm) [Tables A, B, C, D].
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Genes altered by BP treatment

2

1
3
3
2

1

Cluster 1: BP versus SC - up-regulated

Cluster 2: BP versus SC - down-regulated

genes

genes

Genes altered by Pre CHL + co-treatment

A

B

2

3

3
5

1
2

1

Clusters 3(A) and 3(B): Pre CHL + co-treatment versus SC - up-regulated genes

1

3
2

Cluster 4: Pre CHL + co-treatment versus
SC - down-regulated genes

Figure 9: Correlation coefficient gene-expression
clusters created from genes altered significantly in all 6
donors on comparison of the respective treated groups
versus solvent control (SC). Each point on each cluster
was calculated using the average signal generated by
the respective treatment: 1= SC, 2 = BP alone and 3 =
pre CHL + co-treatment. The number of genes/probes
displaying the respective cluster pattern are shown in
parenthesis besides each cluster. The correlation
coefficient (CC) of the genes following the respective
cluster pattern is shown below each cluster. Details
about the exact genes in each cluster following the
respective cluster pattern can be found at
(http://www.cdc.gov/niosh/ext-suppmat/MTP/index.htm) [Tables G, H, I and J].
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Table 6: Table representing the number and characteristics of the probe sets used to
generate the clusters displayed in Figure 9
Number of
probes common
to all 6 NHMECs
altered by
respective
comparison

Number of probes
common to all 6
NHMECs altered
significantly (p<
0.05) by the
respective
comparison

Number of
significantly
altered probes (p<
0.05) exhibiting
common clustering
pattern

Correlation
coefficient
of probes
belonging
to
respective
cluster

BP versus control vehicle
(up-regulated)

391

106

71

0.99

BP versus control vehicle
(down-regulated)

383

134

96

0.93

228

46

39, 3

0.99, 0.99

232

41

40

0.99

Comparison

Pre CHL + co- treatment
versus control vehicle
(up-regulated)
Pre CHL + co- treatment
versus control vehicle
(down-regulated)
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interaction of BP and CHL coming together in a pre CHL + co-treatment of which 15 genes
were up-regulated and 9 were down-regulated by SLR ≥ 1.5. The expression of IL1B and
SECTM1 were consistently up-regulated by BP in most individuals with M99016
exhibiting the greatest expression with SLR ≥ 1.5. Both genes also exhibited the greatest
expression in M99016 on pre-treatment with CHL followed by co-treatment. A graphical
display of all altered immune genes was also generated using Cluster and Tree View
according to the average linkage method (Sokal et al. 1958) and is presented in Figure 10.
Altered immune response genes were analyzed for cross-talks/signal transduction
between themselves and with other cellular entities as well as other cellular pathways.
Though the altered genes are fed as gene names to Pathway Studio, the software takes them
as corresponding proteins while constructing interactions between the input entities as well
as all other entities within the cell. When genes altered by BP treatment versus SC were
queried for all possible interactions with all other molecules and processes within the cell
using Pathway Studio, a total of 2248 relationships/interactions involving 1485 entities
including proteins, small molecules, and various functional classes of molecules,
complexes and cellular processes were found to be involved. When only ‘shortest crosstalk’ interactions were considered for the above genes only 60 relationships were found
between 249 entities. However, there were no direct interactions between the 5 altered
genes (Figure 11). More details about the various interactions among the immune response
genes altered by comparison of BP versus SC can be found at
(http://www.cdc.gov/niosh/ext-supp-mat/IR_Genes/index.htm) (IR-BP genes).
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BP versus
control
vehicle

Pre CHL + co
versus control
vehicle

BP versus control
vehicle-up-regulated
BP versus control vehicledown-regulated genes

Pre CHL + co treatment
versus control vehicleup-regulated genes

Pre CHL + co-treatment
versus control vehicledown-regulated genes

Figure 10: Graphical representation (generated using Cluster and Tree View software)
of all immune response genes altered by SLR ≥ 1.5 on Hu-Gene 133A arrays in at least one
of the 6 NHMECs on treatment with BP or pre CHL + co-treatment. A complete listing of
all the above immune response genes along with their corresponding FCs can be found at
(http://www.cdc.gov/niosh/ext-supp-mat/IR_Genes/index.htm) [IR genes with FC table]
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Figure 11: Five immune response genes were altered by SLR ≥ 1.5 on Hu-Gene 133A
arrays in at least one of the 6 NHMECs on exposure to BP alone. These five immune
response genes were queried for any direct interactions between themselves using Pathway
Studio software. The software takes the input genes as the corresponding proteins while
trying to construct any interactions between the respective members. In this case, no direct
interactions were observed between any of the input entities. The different immune
response proteins are shown according to their respective cellular location.
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Genes altered by pre CHL + post co-treatment were found to exhibit 5782
interactions among and between 2299 entities within the cell. Of these 379 entities
including the altered genes were found to be involved in 704 ‘shortest cross-talk’
interactions. However, there were only 51 direct interactions between the altered genes
(Figure 12). More details about the various interactions among the immune response genes
altered by comparison of pre CHL + post co-treatment can be found at
(http://www.cdc.gov/niosh/ext-supp-mat/IR_Genes/index.htm) (IR-CHL genes). It must be
mentioned that since Pathway Studio relies largely on PubMed to construct interactions and
since the content of PubMed is highly ‘dynamic’, the nature and number of interactions
between the same input members and all other cellular entities are likely to vary with time.
Using ArrayXPath software, 2 (IL1B and MAL) out of the 5 genes altered by BP
were found to have a statistically significant association (p < 0.05) with 5 Biocarta
pathways (Table 7). A total of 45 pathways in GenMAPP, 9 pathways in PharmGKB, 70
pathways in KEGG pathways and 346 Biocarta pathways were queried by Array X to
obtain the above associations. A total of 2 (CD80 and CD86) out of 23 genes altered by pre
CHL + post co-treatment were involved in one GenMAPP pathway and 6 genes (SLP1,
IL8, IL1B, IL1RN, CD80 and CD86) were found to be involved in 13 Biocarta pathways
(Table 8).
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Interaction legend

Figure 12: Twenty four immune response genes were altered by SLR ≥ 1.5 on Hu-Gene
133A arrays in at least one of the 6 NHMECs on treatment with pre CHL + co-treatment.
IL8 was up-regulated by SLR ≥ 1.5 in some of the NHMECs but down-regulated by SLR ≥
1.5 in the others and therefore represented in common in list of up-regulated and downregulated genes. These twenty four immune response genes were queried for any direct
interactions between themselves using Pathway Studio software. The software takes the
input genes as the corresponding proteins while trying to construct any interactions
between the respective members. Fifty one direct interactions were observed between the
input entities. The different immune response proteins are shown according to their
respective cellular location. Genes with no direct interactions between themselves are
shown as separate entities.
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Table 7: Pathways in which immune response (IR) genes altered by SLR ≥1.5 on HuGene133A arrays on comparison of BP treated cells versus control vehicle are involved.
A total of 5 IR genes were altered by SLR ≥1.5 of which 2 (40%) (IL1B, MAL) were found
to possess a statistically significant association (p≤ 0.05) with the above pathways. For
genes involved in more than one pathway, a q value (q≤ 0.05, equivalent to p value)
accounts for the multiple-comparison.
Identified
node

p-value

q-value

BioCarta//Hs_IL 5 Signaling Pathway

1/8 (19)

0.0101

0.0154

BioCarta//Hs_NFkB activation by Nontypeable Hemophilus
influenzae

1/24 (43)

0.0300

0.0230

BioCarta//Hs_Signal transduction through IL1R

1/30 (41)

0.0374

0.0230

BioCarta//Hs_Role of MAL in Rho-Mediated Activation of SRF

1/19 (26)

0.0238

0.0230

BioCarta//Hs_Msp/Ron Receptor Signaling Pathway

1/6 (27)

0.0075

0.0232

Pathway
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Table 8: Pathways in which immune response (IR) genes altered by SLR ≥1.5 on HuGene133A arrays on comparison of CHL treated cells (pre CHL + co-treated) versus
control vehicle are involved. A total of 23 IR genes were altered by SLR ≥1.5 of which 6
(26%) (SLP1, IL8, IL1B, IL1RN, CD80 and CD86) were found to possess a statistically
significant association (p≤ 0.05) with the above pathways. For genes involved in more
than one pathway, a q value (q≤ 0.05, equivalent to p value) accounts for the multiplecomparison.
Identified
node

p-value

q-value

BioCarta//Hs_Proepithelin Conversion to Epithelin and Wound
Repair Control

2/6 (40)

0.0002

0.0018

BioCarta//Hs_The Co-Stimulatory Signal During T-cell
Activation

2/16 (40)

0.0014

0.0072

BioCarta//Hs_NFkB activation by Nontypeable Hemophilus
influenzae

2/24 (43)

0.0032

0.0110

BioCarta//Hs_Signal transduction through IL1R

2/30 (41)

0.0049

0.0128

BioCarta//Hs_Free Radical Induced Apoptosis

1/10 (11)

0.0373

0.0430

BioCarta//Hs_IL 5 Signaling Pathway

1/8 (19)

0.0299

0.0430

BioCarta//Hs_Msp/Ron Receptor Signaling Pathway

1/6 (27)

0.0225

0.0430

BioCarta//Hs_B Lymphocyte Cell Surface Molecules

1/9 (10)

0.0336

0.0430

BioCarta//Hs_Antigen Dependent B Cell Activation

1/10 (24)

0.0373

0.0430

BioCarta//Hs_IL 17 Signaling Pathway

1/15 (16)

0.0554

0.0443

BioCarta//Hs_Regulation of hematopoiesis by cytokines

1/15 (41)

0.0554

0.0443

BioCarta//Hs_Adhesion and Diapedesis of Lymphocytes

1/14 (47)

0.0518

0.0443

BioCarta//Hs_Adhesion and Diapedesis of Granulocytes

1/15 (49)

0.0554

0.0443

BioCarta//Hs_Cells and Molecules involved in local acute
inflammatory response

1/17 (19)

0.0626

0.0459

BioCarta//Hs_Th1/Th2 Differentiation

1/18 (88)

0.0662

0.0459

BioCarta//Hs_Cytokine Network

1/22 (103)

0.0804

0.0522

BioCarta//Hs_Cytokines and Inflammatory Response

1/27 (78)

0.0979

0.0598

GenMapp//Hs_Inflammatory_Response_Pathway

2/29(29)

0.0004

0.0004

Pathway
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4.2 RT-PCR
4.2.1 Confirmation of gene expression on microarrays
Confirmation of gene expression patterns on microarrays was carried out through
RT-PCR for a selected subset 24 genes altered by SLR≥ 1.5 in both replicates in at least
one of the 6 NHMECs. Of these, 7 were immune response genes. The results of RT-PCR
confirmation are presented in Tables 9A, 9B and 10. A more extensive version of Tables
9A and 9B can be found in Table E and Table F, respectively at
(http://www.cdc.gov/niosh/ext-supp-mat/MTP/index.htm). For genes altered by BP, there
was a very good correlation of FC as measured by GC and RT-PCR for all genes except for
CALB1 and SECTM1 which exhibited only a moderate correlation and MERTK which
exhibited a very poor correlation. A very good correlation of FC between GC and RT-PCR
was also observed for all genes altered on pre-treatment with CHL followed by cotreatment except for AKR1C2, DHRS3 and MCM5 which exhibited only a moderate
correlation.
As for the immune response genes there was a good correlation for some genes
while the remaining correlated moderately to poorly (Table 10). Upon BP treatment there
was a good correlation for 1L1B and CXCL2, a moderate correlation for PI3 but a poor
correlation for the remaining genes (SECTM1, IL1RN, CD86 and MX1). However, more
genes had a better correlation on pre CHL + co-treatment. IL1RN and PI3 also exhibited a
good correlation of expression on GC versus RT-PCR apart from 1L1B and CXCL2 while
CD86 and MX1 exhibited a moderate correlation.
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Table 9A: Correlation of fold change (FC) on Hu-Gene 133A arrays/gene-chip (GC) and RT-PCR for a partial list of genes altered
by SLR≥1.5 in at least one of the 6 NHMECs when treated with BP alone. A more extensive version of this table can be found at
(http://www.cdc.gov/niosh/ext-supp-mat/MTP/index.htm) [Table E].
Gene

Probe ID

Accession no.

CYP1B1
CYP1A1
ALDH1A3
MERTK
CALB1
SECTM1
SGK
CTGF
PPP1R3C

202437_s_at
205749_at
222168_at
206028_s_at
205625_s_at
213716_s_at
201739_at
209101_at
204284_at

NM_000104
NM_000499
NM_000693
NM_006343
NM_004929
NM_003004
NM_005627
NM_001901
NM_005398

1 (M98035)
GC
RT-PCR
6.76
1.68
3.23
7.25
-1.37
3.06
-1.46
-2.64
-1.47

±
±
±
±
±
±
±
±
±

0.99
0.87
1.09
1.06
3.35
0.60
0.07
0.00
0.22

10.14
10.48
4.54
0.67
0.48
3.07
0.61
0.48
0.64

±
±
±
±
±
±
±
±
±

0.46
1.47
0.44
0.47
0.09
0.31
0.12
0.09
0.08

2 (M99005)
GC
RT-PCR
3.62
1.65
3.03
1.57
-1.27
2.17
-1.41
-1.63
1.11

±
±
±
±
±
±
±
±
±

0.53
0.92
0.00
0.60
4.26
0.93
0.00
0.16
0.05

7.61
14.50
3.44
1.59
0.90
4.28
0.78
0.90
0.82

±
±
±
±
±
±
±
±
±

0.32
0.79
0.53
0.64
0.04
0.45
0.16
0.04
0.08

BP alone vs vehicle control ( avg. FC ± SD)
3 (M98015)
4 (M98025)
GC
RT-PCR
GC
RT-PCR
11.72
11.34
14.43
1.57
-1.42
2.65
-1.41
-1.63
-1.87

±
±
±
±
±
±
±
±
±

0.57
1.11
0.71
0.60
0.14
0.26
0.00
0.16
0.00

32.10
47.62
7.74
2.06
0.53
7.48
0.62
0.53
0.52

±
±
±
±
±
±
±
±
±

0.85
2.64
0.59
0.33
0.05
2.33
0.11
0.05
0.01

5.55
8.59
-1.96
0.27
0.06
2.38
-1.94
-2.81
-1.28

±
±
±
±
±
±
±
±
±

1.35
0.84
5.80
2.25
2.55
0.12
0.28
0.95
0.19

7.52
15.92
3.14
1.94
0.38
6.55
0.54
0.38
0.61

±
±
±
±
±
±
±
±
±

2.41
2.62
0.67
1.88
0.09
0.51
0.02
0.09
0.14

5 (M99025)
GC
RT-PCR
13.46
1.32
1.44
1.42
3.26
1.52
-1.43
-1.43
-1.83

±
±
±
±
±
±
±
±
±

0.66
0.13
0.42
0.14
0.32
0.15
0.28
0.28
0.44

21.58
9.83
3.84
NA
1.68
5.97
0.86
1.05
0.33

±
±
±
±
±
±
±
±
±

2.18
0.99
2.98
0.62
0.86
0.05
0.02
0.03

6 (M99016)
GC
RT-PCR
5.89
9.21
16.65
-2.82
-1.80
3.41
-2.93
-3.56
-3.26

±
±
±
±
±
±
±
±
±

0.86
0.90
2.44
5.86
4.42
0.83
0.14
1.03
0.32

9.28
95.29
14.42
0.92
0.83
10.94
0.37
0.30
0.24

±
±
±
±
±
±
±
±
±

2.35
5.83
2.49
0.27
1.17
0.83
0.04
0.13
0.06

Correlation (r)
GC-RT
BP alone
0.87
0.67
0.90
-0.30
0.20
0.39
0.83
0.85
0.89

NA= no amplification by RT-PCR
= only 5 donors with amplification considered for correlation analysis

Table 9B: Correlation of fold change (FC) on Hu-Gene 133A arrays/gene-chip (GC) and RT-PCR for a partial list of genes altered
by SLR≥1.5 in at least one of the 6 NHMECs when treated with pre-CHL followed by co-treatment. A more extensive version of
this table can be found at (http://www.cdc.gov/niosh/ext-supp-mat/MTP/index.htm) [Table F].
Correlation (r)

Pre CHL + co-treatment vs vehicle control ( avg. FC ± SD)
Gene
AKR1C2
CLDN4
DHRS3
SOD2
CYR61
SERPINB2
MCM5
GADD45B

Probe ID
211653_x_at
201428_at
202481_at
216841_s_at
201289_at
204614_at
216237_s_at
207574_s_at

Accession no.
NM_001354
NM_001305
NM_004753
NM_000636
NM_001554
NM_002575
NM_006739
NM_015675

1 (M98035)
GC
3.04 ± 0.30
7.03 ± 1.37
1.80 ± 0.09
-1.15 ± 0.00
-2.83 ± 0.00
9.52 ± 0.47
-1.87 ± 0.18
-1.87 ± 0.18

RT-PCR
1.62 ± 0.13
4.87 ± 0.39
1.52 ± 0.17
0.66 ± 0.02
0.23 ± 0.01
10.18 ± 1.55
0.33 ± 0.02
0.30 ± 0.03

2 (M99005)
GC
1.74 ± 0.00
-6.06 ± 0.00
-1.19 ± 0.06
-3.14 ± 0.15
-1.11 ± 0.05
-3.14 ± 0.15
1.69 ± 0.25
-1.23 ± 0.12

RT-PCR
1.82 ± 0.06
0.13 ± 0.01
0.96 ± 0.03
0.38 ± 0.06
1.00 ± 0.05
0.25 ± 0.01
1.84 ± 0.52
0.69 ± 0.07

3 (M98015)
GC
2.07 ± 0.10
1.88 ± 0.37
1.76 ± 0.34
1.15 ± 0.00
-1.62 ± 0.00
1.46 ± 0.07
-1.52 ± 0.15
-0.28 ± 1.91

RT-PCR
2.00 ± 0.16
1.43 ± 0.08
2.17 ± 0.94
1.28 ± 0.07
0.53 ± 0.02
1.75 ± 0.14
0.49 ± 0.02
0.79 ± 0.09

4 (M98025)
GC
5.10 ± 0.25
15.13 ± 6.46
3.26 ± 0.32
-1.33 ± 0.26
-2.30 ± 0.00
3.49 ± 0.34
-3.26 ± 0.32
-3.38 ± 0.50

RT-PCR
2.39 ± 0.08
3.71 ± 0.14
1.53 ± 0.16
0.51 ± 0.05
0.27 ± 0.02
2.20 ± 0.28
0.23 ± 0.02
0.16 ± 0.03

5 (M99025)
GC
2.08 ± 0.30
-0.31 ± 2.59
2.30 ± 0.00
-1.15 ± 0.11
-1.80 ± 0.09
-4.00 ± 0.00
-0.07 ± 1.52
-1.57 ± 0.08

RT-PCR
2.25 ± 0.22
0.46 ± 0.04
3.35 ± 0.28
0.87 ± 0.08
0.62 ± 0.05
0.25 ± 0.01
1.34 ± 0.32
0.83 ± 0.15

GC-RT

6 (M99016)
GC
2.22 ± 0.11
3.62 ± 0.53
1.15 ± 0.00
-1.81 ± 0.69
-0.22 ± 1.83
4.46 ± 0.65
-2.35 ± 0.68
-1.37 ± 0.20

RT-PCR
1.76 ± 0.48
0.35 ± 0.04
1.52 ± 0.16
0.11 ± 0.02
0.97 ± 0.15
0.58 ± 0.03
1.08 ± 0.22
0.27 ± 0.02

A negative sign for FC by gene-chip (GC) refers to down-regulation of gene- expression by the corresponding value.
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PreCHL + co
0.50
0.76
0.50
0.83
0.92
0.81
0.37
0.71

Table 10: Correlation of FC on gene-chip (GC) versus RT-PCR for a selected set of
immune response genes altered by SLR ≥ 1.5 in at least one of the 6 NHMECs on
treatment with BP in the absence or presence of CHL

Gene

IL1B

Cell strain

Treatment
BP versus control vehicle FC

GC

RT-PCR

M98035
M99005
M98015
M98025
M99025
M99016

2.00 ± 0.20
1.23 ± 0.00
2.83 ± 0.00

5.21 ± 0.73

2.02 ± 0.39

1.29 ± 0.05

Correlation (r)

Pre CHL + co versus control vehicle FC

GC

RT-PCR

3.68 ± 0.56

3.03 ± 0.00

3.47 ± 3.03

1.68 ± 0.05

-1.46 ± 0.07

0.62 ± -1.46

3.73 ± 0.00

5.61 ± 3.73

2.55 ± 0.12

1.22 ± 2.55

FC by GC vs RT

0.97

1.94 ± 0.28

3.20 ± 0.51

1.32 ± 0.00

1.41 ± 1.32

5.89 ± 0.86

11.52 ± 1.20

5.89 ± 0.86

7.44 ± 5.89

M98035
M99005
M98015
SECTM1
M98025
M99025
M99016

3.06 ± 0.60

2.87 ± 0.34

1.87 ± 0.00

0.65 ± 0.09

2.17 ± 0.93

5.17 ± 1.15

1.64 ± 0.32

1.83 ± 0.29

2.65 ± 0.26

9.22 ± 1.19

1.88 ± 0.37

4.17 ± 0.53

2.38 ± 0.12

4.87 ± 0.96

0.05 ± 1.93

2.07 ± 0.70

1.52 ± 0.15

4.84 ± 0.77

1.23 ± 0.00

1.67 ± 0.18

3.41 ± 0.83

8.76 ± 0.56

3.49 ± 0.34

3.60 ± 0.50

M98035
M99005
M98015
M98025
M99025
M99016

1.32 ± 0.00

1.60 ± 0.13

1.87 ± 0.00

1.33 ± 0.05

1.04 ± 0.05

1.59 ± 0.16

-0.53 ± 1.55

0.53 ± 0.01

1.28 ± 0.06

1.77 ± 0.15

1.52 ± 0.15

1.47 ± 0.06

1.52 ± 0.00

0.93 ± 0.06

3.26 ± 0.32

1.39 ± 0.08

-1.15 ± 0.00

1.39 ± 0.16

-1.19 ± 0.06

1.01 ± 0.10

-0.17 ± 1.76

1.23 ± 0.44

2.25 ± 0.55

1.76 ± 0.36

1.41 ± 0.00

1.66 ± 0.11

2.25 ± 0.55

1.64 ± 0.17

1.19 ± 0.06

1.91 ± 0.11

-1.37 ± 0.07

0.73 ± 0.03

1.21 ± 0.29

1.57 ± 0.17

1.68 ± 0.08

2.28 ± 0.21

1.41 ± 0.00

1.17 ± 0.25

3.04 ± 0.30

1.62 ± 0.09

0.09 ± 1.75

1.94 ± 0.16

1.15 ± 0.11

1.13 ± 0.14

-0.12 ± 1.69

0.78 ± 0.25

1.83 ± 0.44

2.40 ± 1.05

M98035
M99005
M98015
M98025
M99025
M99016

2.82 ± 0.60

1.43 ± 0.28

7.51 ± 0.87

5.63 ± 1.89

1.54 ± 0.07

1.19 ± 0.06

0.48 ± 0.10

-2.08 ± 0.30

1.29 ± 0.09

1.11 ± 0.05

1.40 ± 0.10

1.37 ± 0.07

1.03 ± 0.08

1.42 ± 0.14

1.58 ± 0.97

IL1RN

CD86

PI3

CXCL2

MX1

M98035
M99005
M98015
M98025
M99025
M99016

0.33

0.12

0.28

0.41

3.05 ± 0.17

5.47 ± 0.27

0.05 ± 2.07

0.36 ± 0.13

-2.87 ± 1.22

2.95 ± 0.38

1.69 ± 0.25

5.44 ± 1.15

5.74 ± 3.19

M98035
M99005
M98015
M98025
M99025
M99016

-1.93 ± 0.09

0.70 ± 0.09

-2.08 ± 0.30

0.26 ± 0.04

-1.19 ± 0.06

1.62 ± 0.16

-2.38 ± 0.12

0.53 ± 0.06

1.46 ± 0.07

2.31 ± 0.19

1.04 ± 0.05

1.23 ± 0.12

0.00 ± 2.00

1.05 ± 0.55

-3.04 ± 0.30

0.17 ± 0.02

1.19 ± 0.06

1.97 ± 0.48

-1.37 ± 0.20

0.75 ± 0.04

1.21 ± 0.29

1.67 ± 0.29

1.23 ± 0.12

0.63 ± 0.02

M98035
M99005
M98015
M98025
M99025
M99016

1.32 ± 0.13

1.34 ± 0.08

1.57 ± 0.60

0.55 ± 0.12

1.19 ± 0.06

1.85 ± 0.37

-2.14 ± 0.00

0.19 ± 0.02

1.07 ± 0.11

0.96 ± 0.10

-4.46 ± 0.65

0.10 ± 0.04

1.99 ± 0.67

1.14 ± 0.10

1.28 ± 0.19

0.16 ± 0.04

0.12 ± 1.69

2.02 ± 0.46

-1.33 ± 0.12

0.51 ± 0.36

-1.80 ± 0.09

0.93 ± 0.32

-2.39 ± 0.91

0.20 ± 0.04

0.79

0.16

Correlation (r)

FC by GC vs RT

0.88

0.43

0.76

0.64

0.86

0.77

0.53
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4.2.2 CYP1A1 and CYP1B1 expression in 20 NHMECs on treatment with BP in the
absence or presence of CHL
Wide inter-individual variations were observed both in the induction and modulation of
CYP1A1 (Table 11) and CYP1B1 (Table 12) following treatment of 20 NHMECs with BP in the
absence or presence of CHL. The basal expression of CYP1A1 was highest in M98014 (∆Ct =
11.18) and lowest in M99005 (∆Ct =16.61). The basal expression of CYP1B1 was highest in
M99016 (∆Ct = 4.19) and lowest in M98015 (∆Ct = 9.77). Overall, the average basal expression
of CYP1A in the 20 NHMECs (∆Ct = 13.44) was 53 fold lower than that of CYP1B1 (∆Ct =
7.72). The basal expression in terms of ∆Ct for the 20 NHMECs is presented in Table 13.
All CHL treatments caused mitigation of CYP1A1 and CYP1B1 expression in 18/20 cell
strains (4-88% reduction across the different CHL treatments) and 17/20 cell (4-83% reduction
across the different CHL treatments) strains respectively, compared to those treated with BP
alone.
CHL co-treatment mitigated CYP1A1 and CYP1B1 expression in all 20 cell strains.
CYP1A1 expression in the presence of CHL co-treatment ranged from 2-62 fold (4-75%
reduction compared to cells treated with BP alone) while that of CYP1B1 ranged from 1-36 fold
(4-67% reduction).
Pre CHL + post BP treatment enhanced BP induced CYP1A1 expression in 2/20 cell
strains (3% and 81% in M98011 and M98014, respectively) while decreasing it in the remaining
18/20 cell strains (11-76% reduction). CYP1B1 expression was also enhanced by pre CHL + post
BP treatment in 3/20 cell strains (30%, 20% and 11% in M98019, M98011 and M99006,
respectively) while decreasing it in the remaining 17/20 cell strains (8-60% reduction).
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Table 11: Inter-individual variations in the induction and modulation of CYP1A1 upon
exposure of NHMECs to either BP alone or in combination with CHL
CYP1A1
Treatment
Cell strain
M98019
M98014
M98011
M99021
M99006
M99025
M00004
M98025
M98035
M99005
M99003
M00012
M99004
M98016
M99015
M98030
M98015
M98026
M98013
M99016

1

2

3

4

3.62 ± 1.04

1.85* ± 0.53

3.03 ± 0.63

2.38 ± 0.83

4.57 ± 1.52

2.79 ± 0.25

8.25 ± 1.91

5.90 ± 0.91

5.36 ± 1.98

5.12 ± 0.99

5.50 ± 0.56

4.99 ± 2.63

5.90 ± 1.46

3.73 ± 1.61

3.75* ± 0.36

3.59* ± 0.52

6.46 ± 1.54

4.21 ± 1.01

5.31 ± 0.61

3.49 ± 0.80

6.58 ± 2.94

4.06 ± 1.59

2.62 ± 0.48

1.65* ± 0.46

7.07 ± 2.53

4.02 ± 0.48

4.35 ± 0.81

3.79 ± 1.41

11.22 ± 3.22

6.01* ± 2.61

9.76 ± 1.62

6.94 ± 0.65

13.83 ± 2.89

12.82 ± 2.01

9.70 ± 1.93

5.29* ± 1.58

13.69 ± 1.35

7.89* ± 1.69

8.14* ± 1.11

4.11* ± 1.37

14.27 ± 5.02

10.21 ± 2.29

11.49 ± 1.60

13.02 ± 3.96

17.09 ± 2.89

11.00 * ± 1.72

12.19* ± 2.80

9.82* ± 2.68

20.25 ± 2.06

10.78* ± 3.96

10.54* ± 3.42

11.55* ± 1.58

32.50 ± 3.40

9.99* ± 2.25

13.2* ± 1.35

6.09* ± 2.02

35.88 ± 4.71

20.75* ± 3.02

31.78 ± 2.69

29.91 ± 9.71

44.32 ± 12.41

18.54* ± 1.53

25.50* ± 2.09

15.97* ± 4.05

49.95 ± 6.64

44.79 ± 12.10

42.59 ± 10.52

47.42 ± 9.35

52.71 ± 12.93

38.99 ± 10.16

31.34* ± 11.54

30.27* ± 5.99

66.72 ± 12.10

16.36* ± 6.40

14.72* ± 6.90

8.03* ± 4.95

95.84 ± 9.86

62.36* ± 20.75

62.36* ± 4.82

53.54* ± 5.38

Treatments - 1-BP alone, 2-co-treatment, 3-Pre CHL+ post BP treatment, 4-Pre CHL + co-treatment (Details
of treatments in Materials and methods)
Numbers shown represent fold change ± standard deviation (n = 2) as measured by RT-PCR
* = statistically significant reduction in expression (p ≤ 0.05) compared to expression induced by BP alone
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Table 12: Inter-individual variations in the induction and modulation of CYP1B1 upon
exposure of NHMECs to either BP alone or in combination with CHL
CYP1B1
Treatment
Cell strain
M98019
M98014
M98011
M99021
M99006
M99025
M00004
M98025
M98035
M99005
M99003
M00012
M99004
M98016
M99015
M98030
M98015
M98026
M98013
M99016

1

2

3

4

6.09 ± 0.38

4.40 ± 1.95

7.90 ± 1.00

6.77 ± 1.79

3.49 ± 0.58

2.92 ± 0.90

1.93* ± 0.18

1.86* ± 0.25

4.74 ± 0.86

3.69 ± 0.63

5.69 ± 0.90

6.32 ± 1.53

8.75 ± 1.41

5.78* ± 1.01

6.27* ± 1.20

5.46* ± 0.86

8.92 ± 1.57

5.54* ± 0.44

9.88 ± 3.36

4.80* ± 0.76

22.86 ± 3.92

11.35 ± 3.09

9.19 ± 1.15

6.50 ± 1.26

7.92 ± 2.62

5.10 ± 0.54

7.31 ± 2.91

4.53 ± 1.95

8.41 ± 2.23

4.42* ± 1.81

4.81* ± 1.50

3.88* ± 0.54

9.46 ± 1.89

7.97 ± 1.84

7.31 ± 1.75

3.32 ± 0.40

9.16 ± 1.78

7.48 ± 0.42

5.82* ± 1.65

3.49* ± 1.30

19.66 ± 1.86

13.02* ± 1.22

15.27* ± 0.97

16.48 ± 5.15

17.54 ± 3.14

10.32* ± 1.65

14.67 ± 4.43

11.90* ± 3.29

12.13 ± 1.25

7.67* ± 1.34

6.96* ± 0.72

6.89* ± 0.83

14.65 ± 2.98

6.16* ± 0.61

10.04 ± 5.87

3.86* ± 1.12

33.88 ± 1.73

13.50* ± 2.25

22.59 ± 11.19

19.94* ± 3.73

16.00 ± 4.12

7.01* ± 1.35

6.45* ± 0.99

4.89* ± 1.77

43.41 ± 4.80

35.88* ± 3.30

39.74* ± 9.32

39.26 ± 6.89

31.67 ± 3.34

21.08* ± 1.69

24.21 ± 8.40

23.55 ± 6.40

42.01 ± 6.89

13.95* ± 1.46

11.49* ± 1.88

7.00* ± 3.24

8.94 ± 1.39

8.60 ± 1.61

8.27 ± 1.08

6.92 ± 1.26

Treatments - 1-BP alone, 2-co-treatment, 3-Pre CHL+ post BP treatment, 4-Pre CHL + co-treatment (Details
of treatments in Materials and methods)
Numbers shown represent fold change ± standard deviation (n = 2) as measured by RT-PCR
* = statistically significant reduction in expression (p ≤ 0.05) compared to expression induced by BP alone
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Table 13: Basal CYP1A1 and CYP1B1 expression levels (∆Ct) in the 20 NHMECs
normalized to that of GAPDH

Cell strain

Basal expression levels (∆Ct)
CYP1A1
CYP1B1

M98019
M98014
M98011
M99021
M99006
M99025
M00004
M98025
M98035
M99005
M99003
M00012
M99004
M98016
M99015
M98030
M98015
M98026
M98013
M99016

15.39
11.18
12.92
11.30
12.26
15.05
12.26
12.10
15.05
16.61
13.48
12.78
12.46
13.43
12.34
15.60
12.18
12.99
13.93
15.86

8.67
6.75
7.80
7.62
8.32
8.63
7.03
6.35
7.48
6.06
8.70
7.92
7.65
7.60
9.29
6.62
9.77
8.81
8.84
4.19

Average

13.46

7.71
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Pre CHL + post co-treatment enhanced CYP1A1 expression in 1/20 cell strains (29% in
M98014) while decreasing it in the remaining 19/20 cell strains (5-88% reduction). CYP1B1
expression was enhanced in 2/20 cell strains (11% and 33% in M98019 and M98011 respectively)
while decreasing it in the remaining 18/20 cell strains (10-83% reduction).
There was a poor correlation between CYP1A1 and CYP1B1 induction on treatment with
BP alone (r2 = 0.28) and by pre CHL + post BP treatment (r2 = 0.29) but a moderate correlation on
co-treatment (r2 = 0.41) and pre CHL + post co-treatment (r2 = 0.47) (Figure 13). The correlation
between the percentage modulation in the expression of CYP1A1 to that of CYP1B1 on cotreatment as well as pre CHL + post co-treatment was moderate (r2 = 0.46, 0.41, respectively) and
absent on treatment with pre CHL + post BP (r2 = 0.09) (Figure 14).
This was mainly due to the presence of several outliers in pre CHL + post BP treatment
(M98011 and M98014 for CYP1A1 and M98019, M98011 and M99006 for CYP1B1) and pre
CHL + post co-treatment groups (M98014 for CYP1A1 and M98019 and M98011 for CYP1B1).
Removal of these outliers from the analysis significantly improved the correlation between the
percentage modulation in the expression of CYP1A1 to that of CYP1B1 upon pre CHL + post cotreatment (r2 = 0.73). However, the correlation between the modulation of CYP1A1 to that of
CYP1B1 on pre CHL + post BP treatment improved only marginally (r2 = 0.34).
The correlation (r2) between CYP1A1 expression by BP alone and in the presence of
different CHL treatments was 0.78, 0.78 and 0.64 for co-treatment, pre CHL + post BP treatment
and pre CHL + post co-treatment, respectively (Figure 15). The correlation (r2)
between CYP1B1 expression by BP alone and in the presence of different CHL treatments
was 0.72, 0.66 and 0.57 for co-treatment, pre CHL + post BP and pre CHL + post cotreatment, respectively) (Figure 16).
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Figure 13: Correlation of CYP1A1 expression to that of CYP1B1 in the 20NHMECs
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of CHL
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Figure 16: Correlation of CYP1B1 expression in the absence and presence of CHL
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4.2.3 CYP1A1 and CYP1B1 expression in 2 NHMECs on treatment with BP or B[e]P in
the absence or presence of CHL
With respect to studies on comparison of BP versus B[e]P in the induction of
CYP1A1 and CYP1B1 wide ‘inter’ cell strain differences were observed in the induction and
modulation of both CYP1A1 and CYP1B1 in both M98015 and M98025 on treatment with
BP or B[e]P in the absence or presence of CHL (Figures 17 and 18).
The induction of both CYP1A1 and CYP1B1 by BP was comparatively higher in
M98015 than M98025 (35 fold versus 10 fold for CYP1A1 and 23 fold versus 5 fold for
CYP1B1). Though B[e]P was a very poor inducer of both CYP1A1 and CYP1B1 in M98015
(2 fold and 1 fold, respectively) and M98025 (0.7 fold and 1 fold, respectively) compared to
BP, the induction of CYP1A1 by B[e]P was slightly higher in M98015 compared to M98025
(2 fold versus 0.7 fold). The induction CYP1B1 by B[e]P, however, showed little difference
between M98015 and M98025.
CHL co-treatment caused a statistically significant decrease of BP induced CYP1A1
expression in M98015 and M98025 (30% and 37% respectively, p< 0.05 for both). CHL cotreatment also caused a decrease of BP induced CYP1B1 expression in both M98015 and
M98025 (42% and 21%, respectively) with the reduction in M98015 being statistically
significant (p< 0.05). In the case of B[e]P, all CHL co-treatments caused an increase in the
expression of B[e]P induced CYP1A1 and CYP1B1 in both M98015 (148%, p<0.005 and
219%, p = 0.005, respectively) and M98025 (75%, p<0.005 and 132%, p<0.05 respectively).
Pre CHL + post BP treatment did not mitigate BP induced expression of CYP1A1 in
M98015 (0.17% increase) but did mitigated it in M98025 (29%). The expression of BP
induced CYP1B1 was reduced only slightly in M98015 (5%) but significantly in M98025
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(50%, p<0.05). Pre CHL + post BP treatment caused a mitigation of B[e]P induced CYP1A1
and CYP1B1 expression in M98015 (3% and 4%, respectively) and M98025 (19% and 54%,
respectively).
Pre CHL + co-treatment did not modulate the expression of BP induced CYP1A1 in
M98015 but caused a statistically significant decrease in the expression of CYP1A1 in
M98025 (40%, p<0.05). The expression of CYP1B1 was significantly reduced in both
M98015 and M98025 (35% and 47% respectively, p<0.05 for both). There was a statistically
significant increase in the expression of B[e]P induced CYP1A1 in M98015 (155%, p<0.005)
and M98025 (112%, p<0.05) upon pre CHL + co-treatment. The expression of B[e]P induced
CYP1B1 was increased in M98015 (62%, p<0.05) but decreased in M98025 (25%).
The correlation (r2) of BP induced CYP1A1 expression to that of CYP1B1 expression
across all treatments for M98015 and M98025 was 0.47 and 0.54, respectively. The
correlation (r2) of B[e]P induced CYP1A1 expression to that of CYP1B1 expression across all
treatments for M98015 and M98025 was 0.97 and 0.71, respectively.

89

A

CYP1A1 induction by BP in the absence or presence of CHL

50

Fold change - CYP1A1 - M98015

CYP1A1 induction by B[e]P in the absence or presence of CHL

40

*

30

20

10

0
1

2

3

4

Treatment group

B

20

CYP1A1 induction by BP in the absence or presence of CHL

Fold change - CYP1A1 - M98025

CYP1A1 induction by B[e]P in the absence or presence of CHL

10

*

*

0
1

2

3

4

Treatment group

Figure 17: Comparison of CYP1A1 expression by BP or B[e]P in (A) M98015 and (B)
M98025 in the absence or presence of CHL.
Treatments: 1= BP alone, 2 = co-treatment, 3 = Pre CHL + post BP treatment, 4 = Pre CHL
+ post co-treatment.
* indicates a statistically significant reduction in CYP1A1 expression compared to BP alone
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Figure 18: Comparison of CYP1B1 expression by BP or B[e]P in (A) M98015 and (B)
M98025 in the absence or presence of CHL.
Treatments: 1= BP alone, 2 = co-treatment, 3 = Pre CHL + post BP treatment, 4 = Pre CHL
+ post co-treatment.
* indicates a statistically significant reduction in CYP1B1 expression compared to BP alone
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4.2.4 CYP1A1 and CYP1B1 expression in MCF-7 and M00012 on treatment with BP in
the absence or presence of CHL
Comparison of MCF-7 with a NHMEC (M00012) across various CHL treatments (as
detailed in Table 3 of Materials and Methods) revealed that though basal CYP1A1 expression
was comparable for both MCF-7 and M00012 (∆Ct = 12.8 for both), CYP1B1 expression was
much higher in MCF-7 (∆Ct = 4.37) as compared to M00012 (∆Ct = 7.92). The basal
expression level of CYP1B1 in MCF-7 cells was 348 times that of CYP1A1 whereas that of
M00012 was only 29 times that of CYP1A1. The basal expression of CYP1B1 in MCF-7 was
nearly 12 times that in M00012. The induction of CYP1A1 by BP alone was 114 fold
whereas that of CYP1B1 was only 5 fold in MCF-7. All CHL treatments caused an increase
of BP induced CYP1A1 (16%, 22% and 23% increase on co-treatment, pre CHL + post BP
treatment and pre CHL + post co-treatment, respectively) and CYP1B1 (11%, 12% and 33%
increase on co-treatment, pre CHL + post BP treatment and pre CHL + post co-treatment
respectively) expression. In the case of M00012, all CHL treatments caused a mitigation of
BP induced CYP1A1 (36%, 29% and 43% decrease on co-treatment, pre CHL + post BP
treatment and pre CHL + post co-treatment, respectively) and CYP1B1 (41%, 16% and 32%
decrease on co-treatment, pre CHL + post BP treatment and pre CHL + post co-treatment,
respectively).
The overall correlation of CYP1A1 expression to that of CYP1B1 expression across
all treatments was moderate for MCF-7 and good for M00012 (r2 = 0.61 and 0.80 for MCF-7
and M00012, respectively).
A comparison of the extent of CYP1 expression between MCF-7 and 20 NHMECs
used in the above studies was also carried out in order to have a comparison against response
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patterns of a broad panel of cell strains. Such a comparison against a broad panel would take
into account inter-cell strains differences in induction and modulation. The basal CYP1A1
and CYP1B1 expression in MCF-7 was higher than the average basal CYP1A1 and CYP1B1
expression across all the 20 NHMECs (∆Ct = 12.81 and 4.37 for CYP1A1 and CYP1B1 in
MCF-7 versus 13.46 and 7.71 for CYP1A1 and CYP1B1 in the 20 NHMECs). This
corresponds to a 2 fold higher expression of CYP1A1 and a10 fold higher expression level of
CYP1B1 in MCF-7 versus the 20 NHMECs. The average basal CYP1B1 expression in the 20
NHMECs was 53 fold that of CYP1A1. The expression patterns of CYP1A1 and CYP1B1 on
treatment of the 20 NHMECs with BP alone or in the presence of different CHL treatments
are presented in Tables 11 and 12, respectively. The induction of CYP1A1 by BP alone in
MCF-7 (114 fold) was much higher than even the highest inducer in the 20 NHMECs (96
fold in M99016). This held true for even the other CHL treatments (co-treatment, pre CHL +
post BP treatment and pre CHL + post co-treatment). With regard to CYP1B1 expression, the
expression in MCF-7 by BP in the absence and presence of CHL was in the range of the 20
NHMECs. Figures 19 and 20 depict the expression patterns of CYP1A1 and CYP1B1,
respectively in MCF-7 and M00012 across the different treatment groups. In each case the
inset shows the expression pattern of MCF-7 in comparison with the other 20 NHMECs.
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Figure 19: (A) CYP1A1 expression patterns on treatment of MCF-7 cells or M00012 (a
NHMEC) with BP in the absence or presence of CHL. (B) CYP1A1 expression patterns in
MCF-7 versus 20 NHMECs. The expression of CYP1A1 in MCF-7 cells is much higher and
different compared to the NHMECs.
Treatments: 1= BP alone, 2 = co-treatment, 3 = Pre CHL + post BP treatment, 4 = Pre CHL
+ post co-treatment.
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Figure 20: (A) CYP1B1 expression patterns on treatment of MCF-7 cells or M00012 (a
NHMEC) with BP in the absence or presence of CHL. (B) CYP1B1 expression patterns in
MCF-7 versus 20 NHMECs. The expression of CYP1B1 in MCF-7 cells was in the range of
the NHMECs.
Treatments: 1= BP alone, 2 = co-treatment, 3 = Pre CHL + post BP treatment, 4 = Pre CHL
+ post co-treatment.
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4.2.5 CYP1A1 and CYP1B1 expression in MCF-7 and M00012 on treatment with BP in
the absence or presence of different CHL concentrations
With regard to the effect of a range of CHL concentrations on BP induced CYP1A1
and CYP1B1 expression in MCF-7 cells, BP induced CYP1A1 expression 38 fold while that
of CYP1B1 was induced only 3 fold. Pre CHL + post co-treatment enhanced BP induced
CYP1A1 expression of cells at low concentrations of CHL (2 μM, 3 μM and 4 μM) in MCF-7
cells. The induction of CYP1A1 was 100 fold, 260 fold and 48 fold on pre-treatment with
CHL 2μM, 3 μM or 4 μM, respectively followed by co-treatment. However, higher
concentrations of CHL (8 μM and 16 μM) mitigated BP induced CYP1A1 expression on pretreatment with CHL followed by the respective post co-treatment, though there did not
appear to be a concentration dependent response. The fold induction of CYP1A1 on pre 8 μM
CHL + post co-treatment and pre 16 μM CHL + post co-treatment was 24 fold and 36 fold,
respectively. The expression of CYP1B1 however was not altered across the different CHL
concentrations in MCF-7. All CHL concentrations caused a slight increase of BP induced
CYP1B1 expression. CYP1B1 expression on treatment of MCF-7 cells with BP alone and in
the presence of 2 μM, 3 μM, 4 μM, 8 μM and 16 μM CHL in a pre CHL + post co-treatment
were 3, 3, 4, 4, 4 and 3 fold, respectively.
In the case of M00012, highest CYP1A1 expression was in the group treated with BP
alone (23 fold) while all CHL treatments except pre 8 μM + post co-treatment mitigated BP
induced CYP1A1 expression to different extents (21, 13, 19, 23 and 2 fold on pre-treatment
with 2 μM, 3 μM, 4 μM, 8 μM and 16 μM CHL followed by co-treatment, respectively).
With respect to CYP1B1 expression, again there did not appear to be a concentration
dependent response. The induction of CYP1B1 by BP was 8 fold whereas the induction in the
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presence of 2 μM, 3 μM, 4 μM, 8 μM and 16 μM CHL pre-treatment followed by cotreatment was 10, 5, 3, 16 and 3 fold, respectively. The correlation (r2) of CYP1A1
expression to CYP1B1 expression by BP in the absence or presence of a range of CHL
concentrations in MCF-7 cells was 0.24 while that in M00012 was 0.41. The expression
patterns of CYP1A1 or CYP1B1 in MCF-7 and M00012 by BP in the absence or presence of
a range of CHL concentrations are shown in Figures 21 and 22, respectively.
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Figure 21: CYP1A1 expression patterns in MCF-7 and M00012 by BP in the
absence or presence of a range of CHL concentrations.

Figure 22: CYP1B1 expression patterns in MCF-7 and M00012 by BP in the
absence or presence of a range of CHL concentrations.
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4.3 DNA adducts
4.3.1 BP-DNA adducts in 20 NHMECs on treatment with BP in the absence or presence
of CHL
The levels of BP-DNA adducts across the 20 NHMECs exhibited considerable interindividual variation with highest levels being in the BP treated group (Table 14). All CHL
treatments lowered BP-DNA adducts in most cell strains except in M99021 (which exhibited an
increase in adduct levels upon co-treatment and pre CHL + post BP treatment) and M99025 (which
showed no reduction in adduct levels upon CHL co-treatment). The number of BP-DNA adducts in
the BP treated group ranged from 2.5 adducts/108 nucleotides (in M99005) to 57.5 adducts/108
nucleotides (M99015).
CHL co-treatment caused a decrease in BP-DNA adduct levels in 18/20 cell strains (1355% reduction) while increasing it in M99021 (5% increase) and having no effect in M99025. The
average reduction in BP-DNA adducts by CHL co-treatment was 33%. Pre CHL + post BP
treatment caused a reduction in BP- DNA adduct levels in 19/20 cell strains (3-67%) while
increasing it in M99021 (12% increase). The average reduction in BP-DNA adducts by CHL pretreatment followed by post BP treatment was 28%. Pre CHL + post co-treatment caused a
reduction in BP-DNA adducts in all cell strains (28-87%). The average reduction in BP-DNA
adducts by CHL pre-treatment followed by post co- treatment was 53%. As evident, the maximum
reduction in BP-DNA adducts for most cell strains was by pre CHL + post co-treatment except in
M99015, M98019 and M99005.
There was a good correlation between the levels of BP-DNA adducts in the presence of BP
alone and by CHL co-treatment (r2 =0.90) as well as pre CHL + post BP treatment (r2= 0.89).
However, their correlation in the presence of pre CHL + post co-was only moderate (r2= 0.68).
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Table14: Inter-individual variations in BP-DNA adduct formation on exposure of NHMECs
to either BP alone or in combination with CHL

BP-DNA adducts/108 nt.
Treatment
Cell strain

1

2

3

4

M99005
M99025
M98014
M99004
M98019
M98035
M99003
M98015
M98030
M99021
M98025
M99006
M98011
M00012
M98013
M00004
M99016
M98016
M98026
M99015

2.45 ± 1.34

1.25 ± 1.20

2.20 ± 2.26

1.50 ± 1.70

3.15 ± 0.64

3.15 ± 0.21

2.50 ± 1.27

1.35 ± 0.07

4.67 ± 0.61

2.24* ± 0.35

2.87* ± 0.15

2.10* ± 0.73

4.75 ± 0.49

2.75 ± 0.64

2.30 ± 0.99

1.90 ± 0.85

5.09 ± 0.94

3.05* ± 1.29

3.22* ± 0.81

3.59 ± 1.11

5.85 ± 3.89

2.70 ± 1.13

5.70 ± 1.56

2.65 ± 1.34

7.25 ± 1.48

3.30 ± 0.28

3.45 ± 1.20

1.30 ± 0.42

8.30 ± 4.95

5.50 ± 3.25

5.45 ± 4.03

4.30 ± 4.10

9.47 ± 1.52

8.12 ± 3.26

5.53 ± 1.78

4.00 ± 1.63

13.66 ± 3.16

14.29 ± 1.49

15.32 ± 3.76

10.21 ± 5.40

15.10 ± 2.40

5.10 ± 0.57

4.95 ± 1.77

3.70* ± 2.40

17.32 ± 3.70

13.59 ± 3.25

15.49 ± 5.75

12.56 ± 4.14

20.83 ± 13.03

15.33 ± 13.06

17.84 ± 9.19

11.73 ± 9.25

21.0 ± 4.53

14.65 ± 1.77

16.35 ± 3.46

10.85 ± 3.32

23.13 ± 1.96

14.45* ± 2.75

12.18* ± 1.23

3.00* ± 0.91

33.41 ± 6.12

27.05 ± 13.72

28.33 ± 9.63

19.83 ± 12.34

34.00 ± 3.39

23.85 ± 3.61

25.45 ± 2.62

12.50* ± 1.41

53.38 ± 2.52

26.05* ± 2.32

25.59* ± 7.00

7.04* ± 1.37

54.46 ± 29.74

47.29 ± 26.00

42.49 ± 21.40

32.49 ± 18.19

57.49 ± 16.23

34.99 ± 15.88

51.40 ± 12.08

35.43 ± 10.79

`
Treatments - 1-BP alone, 2-co-treatment, 3-Pre CHL+ post BP treatment, 4-Pre CHL + co-treatment (Details of
treatments in Materials and methods)
Numbers shown represent fold change ± standard deviation (n = 2) as measured by CIA
* = statistically significant reduction in expression (p ≤ 0.05) compared to expression induced by BP alone
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4.3.2 BP-DNA and B[e]P-DNA adducts in 2 NHMECs on treatment with BP or B[e]P in
the absence or presence of CHL
In the comparison between M98015 and M98025 on treatment with BP or B[e]P in
the absence or presence of CHL, both cell strains had the highest number of BP-DNA
adducts in cells treated with BP alone (8.3 and 15.1 adducts/108 nucleotides in M98015 and
M98025, respectively). All CHL treatments reduced the levels of BP-DNA adducts in
M98015 (34%, 34% and 48% reduction for co-treatment, pre CHL + post BP and pre CHL +
post co-treatment, respectively) and M98025 (66%, 67% and 76% for co-treatment, pre CHL
+ post BP and pre CHL + post co-treatment, respectively). B[e]P-DNA adducts were not
detectable by synchronous fluorescence spectrometry in B[e]P as well as the CHL treatment
groups (B[e]P co-treatment, pre CHL + post B[e]P treatment and pre CHL + post B[e]P cotreatment ) in both M98015 and M98025. Benzo(a)pyrene-r-7,t-8,c-9,t-10-tetrahydrotetrol
was used as a standard to construct the standard curve and the synchronous spectra of one of
the dilutions is shown in Figure 23. Similarly, the synchronous spectra of the B[e]P treated
cells in M98015 and M98025 are shown in Figure 24.
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Figure 23: Synchronous fluorescence spectra obtained from standard
benzo(a)pyrene-r-7,t-8,c-9,t-10-tetrahydrotetrol. The spectra shown here
was generated using 80fM of the standard
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Figure 24: Synchronous spectra of the B[e]P treated cells (A) M98015 and
(B) M98025
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4.3.3 BP-DNA adducts in MCF-7 and M00012 or 20 NHMECs on treatment with BP in
the absence or presence of CHL
Comparison of adducts formed in MCF-7 versus M00012 (NHMEC) following
treatment with BP alone or in the presence of CHL, MCF-7 exhibited adduct levels greater
than 25 orders of magnitude of that of M00012 for all the treatment groups (BP alone, cotreatment, pre CHL + post BP treatment and pre CHL + post co-treatment). 609 BP-DNA
adducts /108 nucleotides were detected in MCF-7 on treatment with BP alone as opposed to
only 21 BP-DNA adducts /108 nucleotides in M00012. None of the CHL treatments
mitigated BP-DNA adduct levels in MCF-7 (3% reduction on co-treatment, 17 and 6%
increase, pre CHL + post BP treatment and pre CHL + post co-treatment, respectively).
M00012 on the other hand exhibited a reduction of BP-DNA adduct levels in all CHL
treatment groups (30%, 22% and 48% reduction on co-treatment, pre CHL + post BP
treatment and pre CHL + post co-treatment, respectively).
In comparison with 20 NHMECs, MCF-7 cells exhibited adduct levels greater than
10 orders of magnitude than the highest number of adducts formed in the 20 NHMECs. This
was true across all treatment groups (BP, co-treatment, pre CHL + post BP treatment and pre
CHL + post co-treatment). The average reduction of BP-DNA adducts across different CHL
treatments among the 20 NHMECs were 33%, 28% and 53% on co-treatment, pre CHL +
post BP treatment and pre CHL + post co-treatment, respectively as opposed to no mitigation
in BP-DNA adduct levels in MCF-7 across the different CHL treatments. The adduct levels
in MCF-7 and M00012 on treatment with BP in the absence or presence of CHL are
presented in Figure 25.
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Figure 25: BP-DNA adduct levels/108 nucleotides in MCF-7 and M00012 on treatment
with BP in the absence or presence of different CHL treatments. The inset on the right
shows the BP-DNA adduct levels in MCF-7 versus that in 20 NHMECs.
Treatments: 1= BP alone, 2 = co-treatment, 3 = Pre CHL + post BP treatment, 4 = Pre
CHL + post co-treatment.
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4.3.4 BP-DNA adducts in MCF-7 and M00012 on treatment with BP in the absence or
presence of different CHL concentrations
When compared across a range of CHL concentrations, CHL did not imitate the level
of BP-DNA adducts across different CHL concentrations in MCF-7 cells. There was no
concentration dependent response and even the highest concentration of CHL (16 μM) did
not cause any reduction in the level of BP-DNA adducts. However, there was concentration
dependent reduction in the levels of BP-DNA adducts in M00012 for all CHL concentrations
except for pre-treatment with 2 μM CHL followed by co- treatment (8% increase compared
to cells treated with BP alone). The reduction in BP-DNA adduct levels across all the other
CHL treatments were 19%, 25%, 36% and 66% for pre-treatment with 3 μM, 4 μM, 8 μM
and 16 μM CHL followed by co-treatment respectively. The reduction in adduct levels at the
higher concentrations of CHL (8 μM and 16 μM) was significant (p<0.05). The levels of BPDNA adducts in MCF-7 were more than 13 fold that in M00012 for BP at the lower
concentrations of CHL (BP, 2 μM and 3 μM CHL pre-treatment followed by co-treatment),
more than 24 fold for both 4 μM and 8 μM CHL pre-treatment followed by co-treatment) and
82 fold for the highest concentration of CHL (pre-treatment with CHL 16 μM followed by
co-treatment). The response patterns of MCF-7 and M00012 across a range of CHL
concentrations are shown in Figure 26.
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Figure 26: BP-DNA adduct levels/108 nucleotides in MCF-7 and M00012 on treatment
with BP in the absence or presence of a range of CHL concentrations. Inset shows a
clearer picture of the response pattern of M00012.
* indicates statistically significant reduction compared to cells treated with BP alone
Treatments: 1= BP alone, 2 = Pre 2 μM CHL + post co-treatment, 3 = Pre 3 μM CHL +
post co-treatment, 4 = Pre 4 μM CHL + post co-treatment, 5 = Pre 8 μM CHL + post cotreatment, 6 = Pre 16 μM CHL + post co-treatment
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4.4 Correlation of CYP1 gene expression to BP-DNA adducts
4.4.1 Correlation of cell strain origin with CYP1 gene expression and DNA adduct
formation
To examine the existence of a relationship, if any, between age of the donors and
inter-individual variability in the induction of CYP1 enzymes and DNA adduct formation, a
correlation analysis of age versus the CYP1 expression and DNA adduct levels was carried
out across the 20 NHMECs used in the study. There was no correlation between age of the
donors and CYP1A1 expression (r2 = 0, 0.02, 0.02 and 0.07 for BP, co-treatment, pre CHL +
post BP treatment and pre CHL + post co-treatment, respectively), CYP1B1 expression (r2 =
0.04, 0.15, 0.13, and 0.22 for BP, co-treatment, pre CHL + post BP treatment and pre CHL +
post co-treatment, respectively) and BP-DNA adduct formation (r2 = 0.10, 0.11, 0.10 and
0.07 for BP, co-treatment, pre CHL + post BP treatment and pre CHL + post co-treatment,
respectively).

4.4.2 Correlation of CYP1 expression to DNA adducts in 20 NHMECs on treatment
with BP in the absence or presence of CHL
In order to understand the contribution and relevance of the Ahr mechanism to BP
metabolism, a correlation of CYP1A1 and/or CYP1B1 expression to the level of BP-DNA
adducts was carried out. Also, the correlation (r2) of CYP1A1 expression in the presence of
BP alone, co-treatment, pre CHL + post BP treatment and pre CHL + post co-treatment to the
levels of BP-DNA adducts by the corresponding treatments was 0.19, 0.16, 0.16 and 0.13,
respectively. Similarly, the correlation (r2) of CYP1B1 expression in the presence of BP
alone, co-treatment, pre CHL + post BP treatment and pre CHL + post co-treatment to the
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levels of BP-DNA adducts by the corresponding treatments were 0.09, 0.03, 0.11 and 0.12,
respectively. Also, since both CYP1A1 and CYP1B1 are involved in the metabolism of BP, a
correlation analysis of the extent of CYP1A1 + CYP1B1 expression by BP alone, cotreatment, pre CHL + post BP treatment and pre CHL + post co-treatment to the levels of
BP-DNA adducts by the corresponding treatments was also carried out. The correlation (r2)
CYP1A1 + CYP1B1 expression on treatment with BP alone, co-treatment, pre CHL + post BP
treatment and pre CHL + post co-treatment to the levels of BP-DNA adducts by the
corresponding treatments were 0.17, 0.13, 0.18 and 0.15, respectively. The basal expression
of CYP1B1 was higher than that of CYP1A1.

4.4.3 Correlation of CYP1 expression to DNA adducts in 2 NHMECs on treatment with
BP or B[e]P in the absence or presence of CHL
In a comparative study between BP and B[e]P across 2 NHMECs (M98015 and
M98025), there was no correlation between BP induced CYP1A1 expression and the level of
BP-DNA adducts in the absence and presence of CHL in M98015 (r2 = 0.02). However, there
was a very good correlation in M98025 (r2 = 0.94). BP induced CYP1B1 expression in the
absence and presence of CHL correlated moderately with the level of BP-DNA adducts in
M98015 (r2 = 0.47) and well in M98025 (r2 = 0.74). Correlation of BP induced CYP1A1 +
CYP1B1 expression with the level of BP-DNA adducts was poor (r2 = 0.20).
Although B[e]P induced a low level of CYP1 expression, as mentioned in section
4.3.2 it did not form a detectable level of DNA adducts.
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4.4.4 Correlation of CYP1 gene expression to DNA adducts in MCF-7 and M00012 or 20
NHMECs on treatment with BP in the absence or presence of CHL
Comparison of CYP1 expression with the level of BP-DNA adducts in MCF-7 versus
M00012 across different treatments (BP, co-treatment, pre CHL + post BP treatment and pre
CHL + post co-treatment) showed a poor correlation for CYP1A1 expression versus BP-DNA
adducts (r2 = 0.33). There was no correlation between CYP1B1 expression versus BP-DNA
adducts (r2 = 0.06). The expression of CYP1A1 + CYP1B1 across all treatment groups versus
BP-DNA adducts by the corresponding treatments was 0.32 and 0.92 for MCF-7 and
M00012, respectively. When compared against all the 20 NHMECs, the correlation (r2) of
CYP1A1 with BP-DNA adducts and CYP1B1 with BP-DNA adducts across all treatment
groups were 0.20 and 0.12, respectively. The expression of CYP1A1 + CYP1B1 across all
treatment groups versus BP-DNA adducts by the corresponding treatments for all 20
NHMECs was 0.21.

4.4.5 Correlation of CYP1 gene expression to DNA adducts in MCF-7 and M00012 on
treatment with BP in the absence or presence of different CHL concentrations
The correlation of CYP1A1 expression versus levels of BP-DNA adducts in MCF-7 cells
on treatment with BP in the absence or presence of different CHL concentrations was poor
(r2 = 0.16) but moderate in M00012 (r2 = 0.54). There was no correlation between CYP1B1
expression versus levels of BP-DNA adducts in both MCF-7 cells (r2 = 0.02) and M00012 (r2
= 0.07). The overall correlation of CYP1A1 + CYP1B1 expression to DNA adducts was poor
for both MCF-7 (r2 = 0.16) and M00012 (r2 = 0.37).
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5.0 DISCUSSION

5.1 Gene expression by microarrays
The development of cancer is a ‘multi-hit’ process requiring perturbation of a number
of normal cellular processes and in turn the function of a multitude of genes that orchestrate
these processes. In this study, we observed alterations both in the extent and patterns of
expression of many genes belonging to different functional categories, on exposure to BP in
the absence or presence of CHL. A complete list of all the genes discussed here can be found
in Tables A, B, C, D at (http://www.cdc.gov/niosh/ext-supp-mat/MTP/index.htm).

5.1.1 Genes altered by BP treatment
Various members of the Phase I and Phase II battery of enzymes were up-regulated
on treatment with BP. The highly consistent increase in the expression of CYP1B1 across all
the 6 NHMEC strains may suggest its possible role as the predominant CYP isoform
involved in the metabolism of BP to DNA binding electrophiles in most individuals. These
results are in agreement with previous studies from our laboratory (45). It also parallels
another study which sought to examine ‘expression signatures’ of tobacco smoke exposure in
a population of 85 individuals using peripheral blood leukocytes. In this study, CYP1B1 was
found to be one of the genes which consistently and significantly correlated with plasma
cotinine concentrations (Lampe et al. 2004). The remaining members of the Phase I cluster of
enzymes up-regulated by BP in this study (CYP39A1, FMO, and CYP1A1) are known to be
involved in the metabolism of steroids and various endogenous substrates in addition to
toxicants. The aldo-keto reductase family 1, member D1 (AKR1D1), an enzyme up-regulated
by BP has been documented to be involved in prevention of oxidative free radical damage
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apart from its role in endogenous aldehyde metabolism (Pappa et al. 2003). Its up-regulation
may indicate to its probable role in the scavenging of any free radicals generated by catalytic
cycling of BP (Porter et al. 1991). The aldehyde dehydrogenases ALDH1A3 and ALDH3A1
have been reported to be involved in aldehyde detoxification generated from alcohol
metabolism and lipid peroxidation.
Given some of the hallmarks of cancer being enhanced uncontrolled cell proliferation
and dysregulation of normal cellular controls it may not be surprising that various genes
possessing diverse roles in transcriptional regulation, cell signaling, cellular proliferation,
cell matrix adhesion and other critical cellular processes may be targets of attack by
carcinogens in different individuals. This might explain the alteration in the expression
patterns of various genes belonging to these categories. They may also represent a response
pattern of the cell to carcinogenic stress as induced by exposure to BP. The up-regulation of
genes like the son of sevenless (SOS) (a guanine exchange factor well known for its role in
Ras activation), STK4 (a serine threonine kinase up-regulated in certain inflammatory breast
cancers (Bieche et al. 2004)), EREG (a member of the epidermal growth factor family found
to exhibit enhanced expression in various epithelial tumors (Yamamoto et al. 2004)) strongly
point to this possibility. In fact, BP has been shown to be capable transforming and
immortalizing cells in vitro (Gudjonsson et al. 2004).
BP is also an immunotoxicant and has been found to lead to T cell suppression
(Rodriguez et al. 1999) and inhibition of B cell lymphopoiesis (Hardin et al. 1992). Among
the battery of immune response genes altered by BP, interleukin 1 beta (IL1B), a
proinflammatory cytokine with a proangiogenic role in vivo, was consistently up-regulated in
all the 6 cell strains on exposure to BP. This may suggest that among the many changes
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occurring following exposure to BP, one of them could be enhanced cell proliferation and
angiogenesis. Also, exposure to BP has been found to affect oxidative damage and immune
system injuries probably necessitating up-regulation of inflammatory cytokines such as IL1B
as a defense mechanism. This is similar to a study where exposure of rats to Fe2O3 or BP or
in combination to study their role in lung cancer resulted in enhanced production of various
inflammatory cytokines including IL1B (Garcon et al. 2001). Of the other immune response
genes up-regulated by BP, MAL, a T cell differentiation proteolipid has been found to
behave as a tumor suppressor (Kazemi-Noureini et al. 2004) and also has a role in apoptosis
(Kohler et al. 1999). Any BP induced cellular damage may be triggering its up-regulation.
Not much is known at this time about the human T-cell leukemia virus enhancer factor
(HTLF). SECTM1 (K12), another immune response gene, is protease inhibitor thought to
have a role in hematopoiesis and in immunogenic processes by acting as CD7 ligand (SlentzKesler et al. 1998). Though initially unknown, CD7 is now known to be involved in T and
NK cell activation and cytokine production. K12 by interacting with CD7 is, therefore,
thought to play a role in regulation of thymocyte signaling and cytokine release (Lam et al.
2005).
Various other genes up-regulated by BP share an unknown association with
carcinogenesis. While some are well characterized genes others appear to be mostly ESTs or
sequences coding for hypothetical proteins. BEX1 and LBH are genes having a role in
developmental regulation being involved in neurogenesis and early limb development,
respectively (Briegel et al. 2001; Koo et al. 2005). Recently, BEX1 has been reported to be
overexpressed in patients with acute myeloid leukemia (Quentmeier et al. 2005). These
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might provide cues to the manner in which BP manifests some of its developmental
toxicities.
Alterations in expression profiles induced by BP appear to be mainly mediated
through up-regulation of genes rather than down-regulation given that only one cell strain
exhibited down-regulation of genes by SLR ≥ 1.5.
Only one gene with a potential role in immune responses (CXCL14) was downregulated by BP. Contradictory reports exist regarding the role of CXCL14 (BRAK) with
some studies pointing more to a role of a tumor suppressor inhibiting tumor growth
(Schwarze et al. 2002; Shellenberger et al. 2004) and yet others reporting a role for it in
enhanced proliferation, migration, and invasion of myoepithelial cells and myofibroblasts
(Allinen et al. 2004).
Taken together, there appears to be a dual role of BP by either enhancing (in most
cases) the expression of genes which may aid in the various aspects of carcinogenesis or in
parallel also modulating the expression of genes which may serve to have a protective effect
by maintaining cellular integrity. Considerable inter-individual variations in response
patterns are also apparent with most genes not being consistently altered in all individuals
except CYP1B1.

5.1.2 Genes altered by Pre CHL + co-treatment
CHL has been documented to modulate various aspects of carcinogenesis and
mutagenesis either through non-specific inhibition of CYPs (Waters et al. 1996), upregulation of various members of the detoxification battery (Singh et al. 1996; Fahey et al.
2005), enhancement of apoptosis (Chiu et al. 2005), modulation of carcinogen transport
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(Mata et al. 2004), mitigation of oxidative stress (Kumar et al. 2004) or various combinations
of these. Alteration in the expression profiles of genes belonging to various functional
categories as seen in this study may point to additional targets of CHL. The large number of
genes modulated by pre CHL + co-treatment may be due a ‘synergistic interaction’ between
BP and CHL.
CHL modulated similar functional classes of genes as those altered by BP though
some of the individual members within each functional class were different. Most members
of the Phase I group of enzymes are common to BP treated cells indicating that their
expression may predominantly be affected by carcinogenic stress (BP) or the fact that CHL
may be a ‘bifunctional inducer’ inducing Phase I enzymes too in addition to Phase II
enzymes or both. Again, only CYP1B1 was consistently up-regulated by SLR ≥ 1.5 (except
M99005) in all the donors while considerable inter-individual variations existed in
expression patterns of the other genes. Several other members of the aldehyde dehydrogenase
and aldo-keto reductase (AKR1) families, apart from the ones altered by BP treatment were
up-regulated by CHL compared to cells treated with BP alone further indicating a
‘bifunctional’ role of CHL. Most of these members were also up-regulated in a consistent
fashion though not by SLR ≥ 1.5 in all 6 donors. Many members of the AKR1 family have
been implicated for their role in the carcinogenesis of organs such as the breast and
endometrium by playing a vital role in progesterone signaling and in turn also regulating the
estrogen: progesterone balance (Bauman et al. 2004; Ji et al. 2004).
Various other genes involved in phenomena as diverse as cell cycle control, apoptosis
and developmental regulation were differentially modulated in different individuals. A
multitude of genes coding for proteins such as kinases, Ca binding proteins, cell junction
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proteins, growth factors, G proteins, various receptors, ligands and other regulatory proteins
involved in various facets of cell signaling were differentially regulated by CHL being ‘up’
in some donors and ‘down’ in others thereby indicating that modulatory effects of CHL may
partly be mediated through modulation of cellular communication processes.
Various immune response genes were also altered differentially by CHL. Genes such
as SLP1, a serine protease (Devoogdt et al. 2003), interleukin 8 (Huang et al. 2002; Mian et
al. 2003), IL1B and several other altered immune response genes have been found to enhance
the risk of different cancers. Their up-regulation by CHL treatment may be explained as the
response possibly mediated by the interactive action of BP +CHL together. Interferon alpha
(IFNA), a gene with the highest degree of up-regulation compared to all other genes (in one
cell strain M99016) has at times been shown to exhibit antitumor effects (Zella et al. 1999).
Its differential regulation in the 6 cell strains could be due to polymorphisms in the gene for
this cytokine or other down stream modulators in the signaling pathway thereby ultimately
leading to differential expression extents and differential effects. CD80 didn’t exhibit upregulation in most of the cell strains except M99016 and has been reported to activate
cytotoxic T lymphocytes (Chan et al. 2004) and also provide negative signals for the
proliferation and IgG secretion of normal B cells and B cell lymphomas (Suvas et al. 2002).
CD86 up-regulated in most of the cell strains has been found to have a role in priming and
activation of naive and memory T cells, respectively (Jeannin et al. 2000) and also for
enhanced activity of B cells (Suvas et al. 2002). PI3, protease inhibitor, up-regulated by CHL
treatment in most of the individuals (except M99005 and M99025) has been reported to have
a role in cell differentiation and apoptosis (Yamamoto et al. 1997) and possibly in the control
of tumor cell invasion (Alkemade et al. 1993).
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A number of other genes with diverse functions, ORF’s and sequences coding for
hypothetical proteins were differentially modulated by CHL and are presently not very well
characterized in relation to cancer. However, many of these are involved in several
developmental processes indicating that developmental processes may also form some key
targets of attack several by some PAHs.
Genes down-regulated by the interactive action of BP + CHL included those whose
enhanced expression has been documented to aid either directly or indirectly the progression
of various cancers, e.g.:SOD2 (Drane et al. 2001), CRY61 (Lin et al. 2005), RAI3 (Wu et al.
2005) and several others. However, various other genes whose enhanced expression is
known to inhibit various facets of carcinogenesis were also down-regulated by the interactive
action of BP + CHL. These included AFT3 (Yan et al. 2005), OCLN (Tobioka et al. 2004),
GADD45B (Qiu et al. 2003), ADAMST1 (Iruela-Arispe et al. 2003), MEST1 (Pedersen et al.
1999) and DOC1 (Schwarze et al. 2002).
Nine genes with a role in immune responses were down- regulated by BP + CHL. Of
these, some like the interferon alpha inducible protein (IFI27) down-regulated in all 6 cell
strains, is a protein suggested to be a novel biomarker of epithelial proliferation and cancer
(Suomela et al. 2004). GIP2 (INSIG1) consistently down-regulated in all the cell strains has
previously been suggested to function intracellularly as a ubiquitin homologue and a
cytokine that induces production of IFN-gamma to augment NK/lymphokine-activated killer
cell proliferation and function, possibly playing a vital role in antiviral response (Zhao et al.
2005). CXCL2 has been implicated in inflammatory responses along with other chemokines
and cytokines (Yamagami et al. 2003) in human corneal endothelium and human melanoma
cells (Gallagher et al. 2005).

116

Not much is known about the role of the remaining genes in relation to cancer and
disease.

5.2 Correlation of gene expression on microarrays versus RT-PCR
Overall, there was a good correlation between the magnitude of expression for
different genes as measured by GC and by RT-PCR. However, there were a few genes which
correlated only moderately to poorly. In general, RT-PCR was more sensitive than GC in
measuring gene expression changes. The lack of good correlation for some genes may be due
to the comparatively lower sensitivity of GC in relation to RT-PCR in addition to differences
in the exact regions being probed by GC and RT-PCR. A low level of expression of
particular gene in only some individuals may cause GC to ‘miss’ it or at most exhibit its
expression at an extremely low level, whereas RT-PCR being more sensitive may be able to
more realistically track its expression giving a higher FC compared to GC culminating in a
poor correlation.
CHL clearly appears to be a ‘bifunctional inducer’ modulating the expression of both
bioactivating and detoxication enzymes. Various other functional categories of genes
modulated by the interactive action of BP + CHL may point to various other presently
unknown targets and mechanisms of action of CHL though these will need to be confirmed.
Some genes (AKR1C1, SECTM1, CRY61 and a few others) following a similar trend of
modulation in most donors though not necessarily by SLR≥ 1.5 in all of them suggest that
these could be good putative ‘biomarkers of exposure’ to be confirmed by further validation.
Many other genes not consistently altered in a similar direction across all donors suggest the
presence of extensive inter-individual variability in response to carcinogenic stress and
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intervention strategies, an issue addressed earlier in our laboratory regarding CYP1A1 and
CYP1B1 (John et al.). However, despite inter-individual differences, CYP1B1 followed by
ALDH1A3 were consistently up-regulated in most individuals following treatment with BP as
well as BP + CHL indicating that these could be definite biomarkers of BP exposure. The
consistent up-regulation of CYP1B1 by BP has been previously reported from our laboratory
(Keshava et al. 2005) and was further confirmed by RT-PCR studies of the 20 NHMEC
strains as discussed below.

5.3 Genetic damage in terms of CYP1 induction and DNA adduct formation in 20
NHMECs on treatment with BP in the absence or presence of CHL
PAHs, including BP, are known to bring about their own metabolism through the Ahr
pathway (Ma et al. 2003). CYP1A1, a substrate inducible enzyme expressed predominantly
in extra hepatic tissues including the breast (Whitlock 1999; Masson et al. 2005) was highly
induced in our studies ( 96 fold variation). Its induction, however, correlated poorly with
donor age. This is in agreement with another study which also found an age independent
variation in the expression of CYP1A1 in normal breast tissue samples (n =58) obtained from
breast cancer patients and normal cancer free individuals (Goth-Goldstein et al. 2000). The
induction of CYP1B1 was much less (43 fold variation) as compared to CYP1A1 and also
correlated poorly with the age of the donor. In contrast to CYP1A1, CYP1B1 is expressed
constitutively in various extra hepatic tissues including the breast but exhibits weak induction
by Ahr ligands which may explain its lower induction in our study compared to CYP1A1 (Ma
et al. 2003).
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The wide inter-individual differences among the cell strains in the induction of both
CYP1A1 and CYP1B1 could be explained at least in part due to polymorphisms in the genes
coding for CYPs and other Phase I enzymes, AhR-Arnt as well as detoxication and repair
enzymes (Ma et al. 2003; Weston et al. 2005). In addition, physiological factors (such as the
presence of endogenous agonists or antagonists), environmental and dietary exposures of the
donors could also play a role although these are much less likely, since the cells have been in
culture for long. Given the fact that majority of the cell strains were of Caucasian origin,
variability due to ethnic differences though low cannot be ruled out completely. The presence
of only a moderate to poor correlation between the induction of both CYP1A1 and CYP1B1
both in the absence and presence of CHL may suggest that both of these isoforms could be
differentially regulated in response to BP or the fact that one isoform may be involved to a
greater extent in carcinogen metabolism than the other or both. In fact, CYP1B1 has been
found to be catalytically more active than CYP1A1 in the bioactivation of different PAHs
(Shimada et al. 1996).
The universal reduction in the induction of both CYP1A1 and CYP1B1 in all the cell
strains upon co-treatment as well as the existence of a good correlation between the fold
induction upon treatment with BP alone and upon co-treatment (when CHL is present along
with the carcinogen) suggests the action of CHL as an ‘interceptor molecule,’ reducing the
availability of BP to trigger the Ahr pathway. Other in vivo studies have also found highly
effective inhibition when CHL was co-administered with the carcinogen (Dashwood 1997a).
A reduction in CYP1 expression in most individuals upon treatment with CHL prior to
carcinogen exposure (pre CHL + post BP) suggests mitigation of CYP1 expression by
mechanisms other than just carcinogen sequestration. Prior exposure to CHL may in some
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manner alter specific cell signaling circuitry or modulate the abundance of Phase I enzymes
directly or indirectly by altering the genes/proteins involved in the ‘Ahr’ battery.’ This
however, might not be a universal phenomenon and the ‘bifunctional’ nature of CHL may be
coming into play to different extents in different individuals which might in part explain the
increase in CYP1 expression in some individuals upon CHL pretreatment. However, the
exact molecular mechanism of CHL mediated modulation of CYP1 gene expression upon its
administration prior to carcinogen exposure is currently unknown. Pre CHL treatment
followed by co-treatment enables CHL to act both as a chelator and as a modulator of CYP1
gene expression thereby causing a reduction in CYP1 expression in the majority of
individuals and also causing a greater reduction in expression compared to other CHL
treatments where CHL acts predominantly by any one of the above mechanisms. This is
exemplified by the presence of a good correlation between the percentage reduction in the
expression of CYP1A1 to CYP1B1 upon pre-treatment with CHL followed by co-treatment in
the absence of outliers.
The reduction in adduct levels in most of the cell strains on co-treatment again points
to the role of CHL as an ‘interceptor’ molecule sequestering the carcinogen and preventing it
from interacting with DNA. This mechanism, however, requires CHL to be present in large
molar excess compared to the carcinogen (Dashwood 1997a). Non-specific inhibition of
CYPs may also lead to reduced metabolism of the carcinogen in turn leading to reduced
availability of the carcinogen to interact with DNA as in a pre CHL + post BP treatment.
However, the poor correlation between CYP1 expression and DNA-adduct levels may
suggest interplay of Ahr independent mechanisms of activation along with cross-talks with
various other cellular pathways and/or factors. Aldo keto reductases (AKRs) have also been

120

shown to have a role in the metabolism of BP. In this respect, human AKR1A1, AKR1C1–
AKR1C4 have been found to be particularly active in metabolizing BP to reactive quinone
metabolites and also generating of reactive oxygen species. AKR1A1 has been found to
serve a dual role in directly metabolizing the BP-7,8-diols to reactive quinones and also
indirectly trans-activating CYP1B1 (Jiang et al. 2004). A peroxidase pathway for BP
metabolism is also documented to exist (Cavalieri et al. 1995). Though there are hardly any
studies on the role of flavin monooxygenases in BP metabolism it may not be misleading to
assume that these monooxygenases along with various other Phase I enzymes may
potentially play at least a minor role in the metabolism of BP in some individuals. Many of
these processes compete with the CYP pathway for BP metabolism. In addition, basal
expression along with induced CYPs is responsible for metabolism of the compound to toxic
metabolites. Therefore, trying to correlate only induced expression with the extent of BPDNA adducts may give poor correlation. The basal expression levels in terms of RNA copy
number need to be determined in future studies. Also, should CHL be triggering Phase II
metabolic reactions (Fahey et al. 2005) or DNA repair process some of the reactive
metabolites/ adducts formed may either be prevented from interacting with DNA or repaired,
respectively leading to the lack of a good correlation.

5.4 Genetic damage in terms of CYP1 induction and DNA adduct formation in 2
NHMECs on treatment with BP or B[e]P in the absence or presence of CHL
With respect to the studies on comparison of BP versus B[e]P, the lower potency of
B[e]P in inducing CYPs and forming adducts was apparent. BP is a strong PAH receptor
(8S) ligand but a weak PAH-binding protein (4S) ligand whereas B[e]P is mainly a 4S ligand
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but a poor AH receptor ligand (Houser et al. 1992; Sterling et al. 1994). This explains the
overall poor induction of CYP1 by B[e]P compared to BP in both cell strains. However, an
explanation for the differential action of CHL towards B[e]P induced CYP1 expression is
unknown. The enhancement in CYP1 expression in most cases involving a co-treatment of
CHL with the carcinogen may suggest a lack of efficient complex formation between B[e]P
and CHL probably due to some change in carcinogen structure and subsequent alteration of
stabilizing forces. In fact CHL has been found to form tight molecular complexes with planar
aromatic hydrocarbons possessing at least partial ring structure when present in large molar
excess to the carcinogen and administered simultaneously with the carcinogen (Dashwood
1997a). CHL in low concentrations has been shown to have the potential to act as an
NADPH generating system by replacing glucose 6-phosphate (Waters et al. 1996). This was
a mechanism suggested for the ‘potentiator effect’ of low concentration of CHL against
nitrosamines (Waters et al. 1996) which was, however, reversed at higher CHL
concentrations. Here, though the concentration of CHL used for intervention of BP and B[e]P
was the same, in the absence of effective complex formation as in the case of B[e]P, the low
concentration of free CHL may have the potential to bring about ‘potentiation’ through the
above mechanism. This suggests that though some carcinogens may be only weakly
carcinogenic they may be rendered more active in the presence of certain chemopreventive
agents which are generally administered to mitigate the ill effects of more potent carcinogens
depending on the concentration and treatment protocol involved. The mechanisms of BPDNA adduct reduction by CHL may occur through some of the above discussed
mechanisms. However, the lack of any detectable adducts by B[e]P in the absence or
presence of CHL, suggests that there may be a very low level of B[e]P-DNA adducts given
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its much lower carcinogenicity compared to BP. In addition, synchronous fluorescence
spectrometry (SFS) may not be sensitive enough to detect rather low levels of adducts
formed by B[e]P (detection limit of 1 in 107 adducts). A more sensitive assay will be needed
to detect these low levels of adducts. The presence of a good correlation between CYP1 gene
expression and BP-DNA adduct formation in M98025 but only a moderate to poor
correlation in M98015 again points to wide inter-individual variation in induction and
response to intervention.

5.5 Genetic damage in terms of CYP1 induction and DNA adduct formation in MCF-7
cells versus an NHMEC (M00012) on treatment with BP or B[e]P in the absence or
presence of CHL
Cancerous cells are often used to study various aspects of carcinogenesis. Their
relative ease of maintenance and faster generation time are some factors which favor their
use. Here, MCF-7, an estrogen receptor positive breast cancer cell line used in comparison
with normal breast cells exhibited a response pattern sharply different from those of normal
cells. CHL failed to mitigate BP induced CYP1 expression and DNA adduct across a range of
CHL treatments and CHL concentrations suggesting that CHL neither behaves as a CYP
inhibitor nor an interceptor molecule in these cells. However, it remains to be determined
whether this is an exclusive response exhibited by MCF-7 cells or is commonly exhibited by
other cancerous cells including other breast cancer cells, some of which may be estrogen
receptor negative. Though the induction of CYP1B1 was low compared to CYP1A1 its basal
expression was much higher than that of CYP1A1. This has been shown even in a few other
studies (McKay et al. 1995; Spink et al. 1998). Nevertheless, it shows that cancerous cells
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exhibit different response patterns compared to normal cells and therefore cannot be used as
surrogates to predict responses of normal cells to carcinogens and chemopreventive agents.
BP is a widely distributed environmental carcinogen and a high risk factor for a
large section of the world’s population whose dietary lifestyle involves use of tobacco.
Smoking alone has been linked to about 30% of all cancer deaths and more than 400,000
premature deaths/year in the U.S. alone (http://www.cancer.org/docroot/PED/ped_10.asp;
http://www.cdc.gov/HealthyYouth/tobacco). A greater understanding of the ‘molecular
changes’ that ensue following PAH exposure can help better design exposure monitoring and
intervention strategies. This study has revealed at least a few potential biomarkers of
exposure some of which could be potential targets for intervention strategies. Clearly,
CYP1B1 is one such target as seen from this study. Additionally, CHL appears to function as
a bifunctional inducer differentially modulating the expression of most genes except a few
where most individuals seem to respond in a similar fashion. Wide inter-individual variations
will need to be accounted for during biomarker validation as well as while designing
intervention strategies.
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6.0 SUMMARY AND CONCLUSIONS

These studies were intended to extend our understanding of human chemical
carcinogenesis, potential biomarkers of carcinogen exposure and strategies for
chemoprevention. To do this a human mammary cell model system was exposed in vitro to
benzo[a]pyrene a known polycyclic aromatic hydrocarbon carcinogen, with or without
chlorophyllin, a potential chemopreventive agent. The effects of these exposures on gene
expression and carcinogenesis precursor events were evaluated.
Global gene expression analysis was carried out to seek for biomarkers of carcinogen
exposure and chemopreventive intervention. Immune response genes altered on exposure to
polycyclic aromatic hydrocarbons, with or without the modulating agent, chlorophyllin, were
analyzed in the context of having cross-talks between themselves as well as interacting with
several other cellular pathways. The expression of cytochrome P450 (CYP1) enzymes
involved in polycyclic aromatic hydrocarbon metabolism was examined across a spectrum of
individuals in relation to their ability to cause DNA damage, in the absence and presence of
chlorophyllin.
CYP1B1 appeared to be a potential biomarker of polycyclic aromatic hydrocarbon
exposure. Chlorophyllin served as an effective chemopreventive agent in mitigating genetic
damage by reducing polycyclic aromatic hydrocarbon metabolism and the extent of DNA
damage.
The main conclusions from the study are that:
•

Genes from a broad spectrum of functional categories were altered by exposure to BP
in the absence or presence of chlorophyllin.
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•

Only CYP1B1 was altered in a consistent manner across all donors, and therefore
appeared to be good biomarker of polycyclic aromatic hydrocarbon exposure and
chemopreventive intervention. All other genes were altered in a less consistent in one
or more donors indicating inter-individual variations in responses.

•

Extensive inter-individual variations were observed in the extent of induction and
modulation of CYP1A1 and CYP1B1 expression as well as benzo[a]pyrene-DNA
adduct formation on exposure to benzo[a]pyrene in the absence or presence of
chlorophyllin.

•

The reduction of CYP1 gene expression and BP-DNA adduct formation in most normal
human mammary epithelial cells suggests the role of chlorophyllin acts as a
‘cytochrome P450 inhibitor’ as well as a ‘chelator’ in mitigating genetic damage.

•

Chlorophyllin may enhance the carcinogenicity of even weakly carcinogenic
polycyclic aromatic hydrocarbons. The extent of enhancement depends on the nature of
the carcinogen as well as the time of chlorophyllin administration as seen from the
enhancement of benzo[e]pyrene induced CYP1 gene expression by pre chlorophyllin
+ post benzo[e]pyrene treatment but not any of the other chlorophyllin treatments.

•

Cancerous MCF-7 cells exhibited high levels of CYP1A1 induction and
benzo[a]pyrene-DNA adduct formation on exposure to benzo[a]pyrene, both in the
absence and presence of chlorophyllin, suggesting probably a different mechanism of
chlorophyllin action in cancerous cell as opposed to normal cells and/or the fact that
MCF-7 may be an inappropriate surrogate to normal mammary cells.

•

Only chlorophyllin concentrations higher than those used in other experiments (8 μM,
16 µM) mitigated BP induced CYP1 gene expression in MCF-7 cells. However, none
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of the chlorophyllin concentrations mitigated BP-DNA adduct formation in MCF-7
cells supporting the previous conclusion.
•

The lack of reduction in the extent of CYP1 gene expression and benzo[a]pyrene-DNA
adduct formation in MCF-7 cells suggests that chlorophyllin performs poorly as a
‘CYP inhibitor’ and ‘chelator’ in MCF-7 cells.
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7.0 FUTURE DIRECTIONS

•

In order to gain a better understanding of the correlation between CYP1 gene
expression and BP-DNA adduct formation an assessment of gene copy number needs
to be determined. This will also help reveal the possible interplay of Ahr independent
mechanisms in the metabolism of BP.

•

The balance between toxicity and detoxication can be better understood if the effects of
CHL on other phase I enzymes, e.g., other monooxygenases, in addition to the phase II
enzyme battery are determined.

•

The effect of chlorophyllin alone on global gene expression would be a valuable asset
to the scientific community involved in screening for new cancer chemopreventive
agents.

•

Studies on functional CYP1 enzyme abundance and activity following exposure of
cells to BP in the absence or presence of CHL will help reveal whether CHL mediated
changes are transcriptionally or translationally regulated and in turn will help gain a
better understanding of the mechanistic aspects of CHL action and BP metabolism.

•

Studies on a wider spectrum of cancerous cells will help determine whether the large
extent of genetic damage as seen in MCF-7 cells (as opposed to NHMECs) is a
common feature of most cancerous cells and in turn point to the feasibility of using
cancerous cells as surrogates to normal cells for studying the carcinogenic process.
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9.0 APPENDIX
Tissue Mix media
Penicillin Streptomycin mix (10,000U/ml Penicillin G sodium and
10,000U/ml Streptomycin sulfate)
Fungizone (250μg/ml Amphothericin and 250μg/ml sodium deoxycholate)
Insulin (10mg/ml)
Hanks buffered saline
Total

10 ml
20 ml
1 ml
969 ml
1000 ml

Filter through 0.2μM filter.
Tissue Digestion media
Tissue mix media
Collagenase (2000U/ml)
Hyaluronidase
Fetal Bovine Serum
Total
Filter through 0.2μM filter.

70 ml
10 ml
10 ml
10 ml
100 ml

Freezing media
MEBM media
DMSO
Fetal Bovine Serum
Total
Filter through 0.2μM filter.

80 ml
10 ml
10 ml
100 ml

MCF-7 media
DMEM (Dulbecco’s modified Eagle’s medium)
Fetal calf serum (FCS)*
Penicillin (5000U/ml)-Streptomycin mix (5000μg/ml) mix
Amphothericin B (250μg/ml)
Insulin (1000 μg/ml)
Total
Filter through 0.2μM filter.
* FCS is to be heated (560C for 50 min) to inactivate components of the
complement system

894.5 ml
100 ml
2 ml
1 ml
2.5 ml
1000 ml

5X RNA Fragmentation buffer
200 mM Tris acetate, pH 8.1
500 mM potassium acetate
150 mM magnesium acetate
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